SV EN

2005 – 2009

Grundforskning

Buervenich S, Carmine A, Galter D, Shahabi HN, Johnels B, Holmberg B, Ahlberg  J, Nissbrandt H, Eerola J, Hellström O, Tienari PJ, Matsuura T, Ashizawa T, Wüllner U, Klockgether T, Zimprich A, Gasser T, Hanson M, Waseem S, Singleton A,  McMahon FJ, Anvret M, Sydow O, Olson L. A rare truncating mutation in ADH1C (G78Stop) shows significant association with  Parkinson disease in a large international sample. Arch Neurol. 2005; 62:74-8.

Holmberg K, Kuteeva E, Brumovsky P, Kahl U, Karlström H, Lucas GA, Rodriguez J, Westerblad H, Hilke S, Theodorsson E, Berge OG, Lendahl U, Bartfai T, Hokfelt T. Generation and phenotypic characterization of a galanin overexpressing mouse.  Neuroscience. 2005;133(1):59-77.

Håkansson A, Westberg L, Nilsson S, Buervenich S, Carmine A, Holmberg B, Sydow O, Olson L, Johnels B, Eriksson E, Nissbrandt H. Investigation of genes coding for inflammatory components in Parkinson’s disease. Mov Disord. 2005; 20:569-73.

Johansson S, Lee IH, Olson L, Spenger C. Olfactory ensheathing glial co-grafts improve functional recovery in rats with 6-OHDA lesions. Brain. 2005; 128:2961-76.

Helena Karlstrom, William S Brooks, John BJ Kwok, Jillian J Kril, Glenda M Halliday, and Peter R Schofield. Variable phenotype of Alzheimer’s Disease with Spastic Paraparesis. Genotype-Proteotype-Phenortype, Relationsship in Neurodegenerative Diseases, IPSEN FOUNDATION, Bokkapitel, 2005

Mattsson A, Lindqvist E, Ogren SO, Olson L. Increased phencyclidine-induced hyperactivity following cortical cholinergic denervation. Neuroreport. 2005; 16:1815-9.

Rahman SMA, Akterin S, Flores-Morales A, Crisby M, Kivipelto M, Schultzberg M, Cedazo-Minguez A (2005) High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice. FEBS Letters, 579, 6411-6416

Spulber S, Moldovan M, Oprica M, Aronsson A, Post C, Winblad B, Schultzberg M. Alpha-MSH decreases core and brain temperature during global cerebral ischaemia in rats. Neuroreport 2005;16(1):69-72

Westerlund M, Galter D, Carmine A, Olson L. Tissue- and species-specific expression patterns of class I, III, and IV Adh and  Aldh 1 mRNAs in rodent embryos. Cell Tissue Res. 2005 322:227-36.

Carmine Belin A, Westerlund M, Sydow O, Lundströmer K, Håkansson A, Nissbrandt H, Olson L, Galter D. Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian. Mov Disord 2006; 21:1731-4.

Elbaz A, Nelson LM, Payami H, Ioannidis JP, Fiske BK, Annesi G, Carmine Belin A, Factor SA, Ferrarese C, Hadjigeorgiou GM, Higgins DS, Kawakami H, Krüger R, Marder KS, Mayeux RP, Mellick GD, Nutt JG, Ritz B, Samii A, Tanner CM, Van Broeckhoven C, Van Den Eeden SK, Wirdefeldt K, Zabetian CP, Dehem M, Montimurro JS, Southwick A, Myers RM, Trikalinos TA with contributions also by: Silburn PA, Nuytemans K, Pals P, Pickut B, De Deyn PP, Theuns J, Tzourio C, Amouyel P, Lambert J-C, Riess O, Bauer P, Gasser T, Berg D, Xiromerisiou G, Galbussera A, Zini M, Goldwurm S,(Parkinson Institute); Gianni Pezzoli G, Quattrone A, Annesi F, Tarantino P, Morino H, Maruyama H, Izumi Y, Kaji R, Pedersen NL, Olson L, Westerlund M, Galter D, Sydow S, McGuire V, Topol B, Wahner A, Bordelon YM, Clark L, Tang M-X, Bronstein J, Brady S, Aggarwal A, Liu X, Griffith A, Leis BC, Roberts JW: Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson’s disease: a large-scale international study. Lancet Neurol 2006; 5:917-23.

Galter D, Westerlund M, Carmine A, Lindqvist E, Sydow O, Olson L. LRRK2 expression linked to dopamine-innervated areas. Ann Neurol. 2006; 59:714-9.

Lavebratt C, Trifunovski A, Persson AS, Wang FH, Klason T, Ohman I, Josephsson A, Olson L, Spenger C, Schalling M. Carbamazepine protects against megencephaly and abnormal expression of BDNF and Nogo signaling components in the mceph/mceph mouse. Neurobiol Dis. 2006; 24:374-83.

Oprica M, Spulber SD, Aronsson A, Post C, Winblad B, Schultzberg M. The influence of kainic acid on core temperature and cytokine levels in the brain. Cytokine 2006; Jul;35(102):77-87.

Trifunovski A, Josephson A, Bickford PC, Olson L, Brené S. Selective decline of Nogo mRNA in the aging brain. Neuroreport. 2006 17:913-6.

Carmine Belin AC, Björk BF, Westerlund M, Galter D, Sydow O, Lind C, Pernold K, Håkansson A, Nissbrandt H, Graff C and Olson L: Association study of two previously reported genetic variants in mitochondrial transcription factor A (TFAM) in Alzheimer’s and Parkinson’s disease. Neuroscience Letters. 2007 420:257-62.

Carmine Belin A, Westerlund M, Bergman O, Nissbrandt H, Lind C, Sydow O, Galter D. S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson’s disease in Sweden. Parkinsonism Relat Disord. 2007 13:295-8.

Blackinton JG, Anvret A, Beilina A, Olson L, Cookson MR and Galter D. Expression of PINK1 mRNA in human and rodent brain and in Parkinson’s disease. Brain Research, 2007, Dec 12, 1184: 10-6.

Brené S, Bjornebekk A, Aberg E, Mathé AA, Olson L, Werme M. Running is rewarding and antidepressive. Physiol Behav. 2007 92:136-40

Cedazo-Minguez A. Apolipoprotein E and Alzheimer’s disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med. 2007 Nov-Dec; 11(6):1227-38.

Cowburn RF, Popescu BO, Ankarcrona M, Dehvari N, Cedaz<o-Minguez A. Presenilin-mediated signal transduction. Physiol Behav. 2007 Sep 10:92(1-2):93-7.

Dehvari N, Cedazo-Minguez A, Isacsson O, Nilsson T, Winblad B, Karlström H, Benedikz E and Cowburn RF. Presenilin Dependence of Phospholipase C and Protein Kinase C Signalling. J. Neurochem. 2007 Apr 16.

Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E, Thams S, Bergstrand A, Hansson FS, Trifunovic A, Hoffer B, Cullheim S, Mohammed AH, Olson L, Larsson NG. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci U S A. 2007 104:1325-30.

Endo T, Spenger C, Tominaga T, Brené S, Olson L. Cortical sensory map rearrangement after spinal cord injury: fMRI responses linked to Nogo signalling. Brain. 2007 130:2951-61.

Folkesson R, Malkiewicz K, Nilsson T, Kloskowska E, Popova E, Bogdanovic N, Ganten U, Ganten D, Winblad B, Bader M, Benedikz E. (2007) A transgenic rat expressing human APP with the Swedish Alzheimer’s disease mutation. Biochem Biophys Res Commun. 358(3):777-82.

Forslin Aronson A, Spulber S, Oprica M, Winblad B, Post C, Schultzberg M. Alpha-MSH rescues neurons from excitotoxic cell death. J Mol Neurosci 2007;33(3):239-51.

Galter D, Westerlund M, Belin AC and Olson L. DJ-1 and UCH-L1 gene activity patterns in the brains of controls, Parkinson and schizophrenia patients and in rodents. Physiol Behav. 2007 92:46-53.

Håkansson A, Bergman O, Chrapkowska C, Westberg L, Belin AC, Sydow O, Johnels B, Olson L, Holmberg B and Nissbrandt H. Cyclooxygenase-2 polymorphisms in Parkinson’s disease. Am J Med Genet B Neuropsychiatr Genet. 2007 144:367-9.

Karlstrom H, Kwok JBJ, Gregory GC, Hallupp M, Brooks WS and Schofield P (2007) No association of spastic paraparesis genes in PSEN1 Alzheimer’s disease with spastic paraparesis. Neuroreport. 2007 Aug 6;18(12):1267-9

Laudon H, Winblad B, Näslund J. The Alzheimer’s disease-associated gamma-secretase complex: Functional domains in the presenilin 1 protein. Physiol Behav 2007 Sep 10;92(1-2):115-20.

Mattsson A, Olson L, Svensson TH and Schilström B. Cortical cholinergic deficiency enhances amphetamine-induced dopamine release in the accumbens but not striatum. Exp Neurol. 2007 208:73-9.

Oprica M, Hjorth E, Spulber S, Popescu BO, Ankarcrona M, Winblad B, Schultzberg M (2007) Studies on brain volume, Alzheimer-related proteins and cytokines in mice with chronic overexpression of IL-1 receptor antagonist. J Cell Mol Med, 11:810-825.

Westerlund M, Belin AC, Felder MR, Olson L and Galter D. High and complementary expression patterns of alcohol and aldehyde dehydrogenases in the gastrointestinal tract: implications for Parkinson’s disease. FEBS J. 2007 Mar;274(5):1212-23.

Bergman O, Håkansson A, Westberg L, Carmine Belin A, Sydow O, Olson L, Holmberg B, Eriksson E, Nissbrandt H. Pitx3 polymorphism is associated to Parkinson’s disease with early onset. Neurobiol Aging 2008, (in press).

Dehvari N, Sandebring A, Flores-Morales A, Mateos L, Chuan YC, Goldberg MS, Cookson MR, Cowburn RF, Cedazo-Minguez A. Parkin-mediated ubiquitination regulates phospholipase C-gamma1. J Cell Mol Med. 2008 Jul 30.

Dehvari N, Isacsson O, Winblad B, Cedazo-Minguez A, Cowburn RF. Presenilin regulates extracellular regulated kinase (Erk) activity by a protein kinase C alpha dependent mechanism. Neurosci Lett 2008 May 2;436(1):77-80.

Dufour E, Terzioglu M, Hansson FS, Sörensen L, Galter D, Olson L, Wilbertz J, Larsson NG. Age-Associated Mosaic Respiratory Chain Deficiency Causes Trans-Neuronal Degeneration. Hum Mol Genet. 2008; 17:1418-26.

Galter D. Recent progress in Parkinson’s disease. Introduction to mini review series. FEBS J. 2008; 275:1369.

Jin S, Hansson E, Ihalainen S, Lanner F, Sahlgren C, Farnebo F, Baumann M, Kalimo H, Lendahl U. (2008) Notch signaling regulates PDGF-receptor eta expression in vascular smooth muscle cells. Circulation Res 102, 1483-91.

Karlstrom H, Brooks, WS, Kwok, JBJ, Broe GA, Kril JK, McCann H, Halliday GM, Schofield PR. Variable phenotype of Alzheimer’s disease with spastic paraparesis. Review. J Neurochem. 2008 104: 573-583

Kivipelto M, Rovio S, Ngandu T, Kåreholt I, Eskelinen M, Winblad B, Hachinski V, Cedazo-Minguez A, Soininen H, Tuomilehto J, Nissinen A. Apolipoprotein E e4 magnifies lifestyle risks for dementia: A population based study. J Cell Mol Med. 2008 Mar 4, (in press).

Kloskowska E, Bruton JD, Winblad B, Benedikz E. (2008) The APP670/671 mutation alters calcium signalin and response to hyperosmotic stress in rat primary hippocampal neurons, (in press).

Kloskowska E, Malkiewicz K, Winblad B, Benedikz E, Bruton JD. (2008) Increased frequency of spontaneous Ca2+ -oscillations in rat hippocampal neurons expressing APPswe. Neuroscience Letters 436(2):250-4.

Mateos L, Akterin S, Gil-Bea F-J, Spulber S, Rahman A, Björkhem I, Schultzberg M, Flores-Morales A, Cedazo-Minguez A. (2008) Activity-regulated cytoskeleton-associated protein in rodent brain is down-regulated by high fat diet in vivo and by 27-hydroxycholesterol in vitro. Brain Pathol. 2008 May 23.

Poellinger L, Lendahl U. (2008) Modulating Notch signaling by pathway-intrinsic and -extrinsic mechanisms. Curr Opinion in Genetics and Development, (in press).

Rauen T, Raffetseder U, Frye BC, Djudjaj S, Muehlenberg PJ, Eitner F, Lendahl U, Bernhagen J, Dooley S, Mertens PR. YB-1 acts as ligand for Notch-3 receptors and modulates receptor activation. J Biol Chemistry (in press).

Sallam H, Jimenez P, Song H, Vita M, Cedazo-Minguez A, Hassan M. Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain. Pharmacol Res. 2008 Jun 8.

Spulber S, Oprica M, Bartfai T, Winblad B, Schultzberg M (2008a) Blunted neurogenesis and gliosis due to transgenic overexpression of  human soluble IL-1ra in the mouse. Eur J Neurosci, 27:549-558

Terzioglu M, Galter D. Parkinson´s disease: genetic versus toxin- induced rodent models. FEBS J 2008; 275:1384-91.

Trifunovic A, Larsson NG. Mitochondrial dysfunction as a cause of ageing. JIM 2008; Feb;263(2):167-78. (Review).

Westerlund M, Carmine Belin A, Anvret A, Bickford P, Olson L and Galter D. Opposite developmental regulation of LRRK1 and LRRK2 mRNA expression in the brain and activity in other human and rodent organs; implications for sites of action of mutated LRRK2 in Parkinson’s disease. Neuroscience, (in press).

Westerlund M, Carmine Belin A, Anvret A, Håkansson A, Nissbrandt H, Lind C, Sydow O, Olson L, Galter D. Cerebellar alpha-synuclein levels are decreased in Parkinson’s disease and do not correlate with SNCA polymorphisms associated with disease in a Swedish material. FASEB J 2008 (in press).

Westerlund M, Carmine Belin A, Olson L, Galter D. Expression of multi-drug resistance 1 mRNA (MDR1) in human and rodent tissues; reduced levels in Parkinson patients. Cell and Tissue Research (in press).

Benedikz E, Kloskowska E, Winblad B. The rat as an animal model of Alzheimer’s disease. Invited review, JCMM 2009; 13(6):1034-1042.

Björkhem I, Cedazo-Minguez A, Leoni V, Meaney S. Oxysterols and neurodegenerative diseases. J Mol Aspects of Medicine 2009 (in press).

Cedazo-Minguez A, Mateos L, Björkhem I. Dysregulation of cholesterol metabolism in Alzheimer’s disease. J Alzh dis 2009 (in press).

Endo T, Tominaga T, Olson L. Cortical changes following spinal cord injury with emphasis on the Nogo signaling system. The Neuroscientist 2009; 15:291-299.

Galter D, Pernold K, Yoshitake T, Lindqvist E, Hoffer B, Kehr J, Larsson N-G, Olson L. MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson’s disease. Genes, Brain and Behavior 2009 (in press).

Karlén A, Karlsson ER, Mattsson A,Lundströmer K, Pham TM, Bäckman CM, Ögren SO, Hoffman AF, Sherling MA, Lupica CR, Hoffer BJ, Spenger C, Josephson A, Brené S, Olson L. Nogo receptor 1 regulates formation of lasting memories. (PNAS, under review)

Kloskowska E, Pham TM, Nilsson T, Zhu S, Öberg J, Codita A, Pederson LO, Pedersen JT, Malkiewicz K, Winblad B, Folkesson R, Benedikz E. Cognitive impairment in the Tg6590 transgenic rat model of Alzheimer’s disease. JCMM (in press).

Perálvarez-Marín A, Mateos L, Singh S, Cedazo-Minguez A, Visa N, Barth A, Gräslund A. Influence of residue 22 in the aggregation profile and toxicity of the Aß peptide. Biophys J 2009 Jul 8; 97(1):277-285

Sandebring A, Dehvari N, Perez M, Thomas KJ, Karpilovski E, Cookson MR, Cowburn RF, Cedazo-Minguez A. Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signaling. FEBS J 2009 (in press).

Sandebring A, Thomas KJ, Beilina A, van der Brug M, Cleland MM, Ahmad R, Miller DW, Cowburn R, Behbahani H, Cedazo-Minguez A, Cookson MR. Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein. PLoS One 2009 May 27; 5(5):e5701.

Spulber S, Oprica M, Winblad B, Bartfai T, Schultzberg M. Impaired long term memory consolidation in transgenic mice overexpressing the human soluble form of IL1ra in the brain. J Neuroimmunol 2009a; 208:46-53.

Spulber S, Bartfai T, Schultzberg M. IL-1/IL-1ra balance in the brain revisited – evidence from transgenic mouse models. Brain Behav Immun 2009c; 23:573-579.

Spulber S, Schultzberg M. Connection between inflammatory processes and transmittor function – Modulatory effects of interleukin-1 in brain function. Progress in Neurobiol (in press).

Westerlund M, Hoffer B, Olson L. Parkinson’s disease: exit toxins, enter genetics. Progress in Neurobiology 2009 (in press).

Winblad B, Cedazo-Minguez A. Biomarkers for Alzheimer’s disease and other forms of dementia: Clinical needs, limitations and future aspects. Exp Gerontology 2009 (in press).

 

​Genetik    

Lindberg MJ, Byström R, Bokanäs N, Andersen PM, Oliveberg M. Systematically perturbed folding patterns of ALS-associated SOD1 mutants. Proc Natl Acad Sci U S A. 2005;102:9754-9759.

Meyer T, Schwan A, Dullinger JS, Brocke J, Hoffmann T, Nolte CH, Hopt A, Kopp U, Andersen PM, Epplen JT, Linke P. Early-onset ALS with long-term survival associated with spastin mutation. Neurology 2005;65:141-143.

Sato T, Nakanishi T, Yamamoto Y, Andersen PM, Ogawa Y, Fukada K, Zhou Z, Aoike F, Sugai F, Nagano S, Hirata S, Ogawa M, MD, Nakano R, Ohi T, Kato T, Nakagawa M, Hamasaki T, Shimizu A, Sakoda S. Rapid disease progression correlates with instability of mutant SOD1 in familial ALS. Neurology 2005;65:1954-1957.

Turner MR, Hammers A, Al-Chalabi A, Shaw CE, Andersen PM, Brooks DJ, Leigh PN. Distinct cerebral lesions in sporadic and ‘D90A’ SOD1 ALS: Studies with [11C]-flumazenil PET. Brain 2005;128:1323-1329.

Bergemalm D, Jonsson A, Graffmo K, Andersen PM, Brannstrom T, Rehnmark A, Marklund SL.Overloading of stable and exclusion of unstable human superoxide dismutase-1 variants in mitochondria of murine amyotrophic lateral sclerosis models. J Neuroscience 2006;26:4147-4154.

Broom WJ, Russ C, Sapp PC, McKenna-Yasek D, Hosler BA, Andersen PM, Brown RH Jr. Variants in candidate ALS modifier genes linked to Cu/Zn superoxide dismutase do not explain divergent survival phenotypes. Neuroscience Letters 2006;392:52-57.

Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, Donaghy C, Paterson V, Swingler R, Morrison KE, Green A,  Acharya KR, Brown Jr RH, Hardiman O. Loss-of-function ANG mutations segregate with familial and ‘sporadic’ amyotrophic lateral sclerosis. Nat Genet 2006;38:411-413.

Jonsson PA, Graffmo KS, Andersen PM, Brännström T, Oliveberg M, Marklund SL. Disulfide-reduced SOD1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain 2006;129:451-464.

Jonsson A, Graffmo KS, Brännström T, Nilsson P, Andersen PM, Marklund SL. Motor neuron disease in mice expressing the wild type-like D90A mutant  superoxide dismutase-1. J Neuropathology Experimental Neurology 2006;65:1126-1136.

Lasn H, Winblad B, Bogdanovic N. Neurologia in the inferior olivary nucleus during normal aging and Alzheimre’s disease. J Cell Mol Med 2006;10(1):145-156.

Morita M, Al-Chalabi A, Andersen PM, Hosler B, Sapp P, Englund E, Mitchell JE, Habgood JJ, de Belleroche J, Xi J, Jongaroenprasert W, Horvitz HR, Gunnarsson L-G, Brown RH. A single locus on chromosome 9p for ALS and frontotemporal dementia. Neurology 2006;66:839-844.

Parkinson N, Ince PG, Smith MO, Highley R, Skibinski G, Andersen PM, Morrison KE, Pall HS, Hardiman O, Collinge J, Shaw PJ, Fisher EMC. ALS phenotypes with mutations in CHMP2B (Charged Multivesicular Body Protein 2B). Neurology 2006;67:1074-1077.

Stewart HG, Mackenzie I, Eisen A, Brännström T, Marklund SL, Andersen PM.Clinicopathologic phenotype of ALS with a novel G72C SOD1 gene mutation presenting with myopathic features. Muscle & Nerve 2006;33:701-706.

Andersson ME, Sjölander A, Andreasen N, Minthon L, Hansson O, Bogdanovic N, Jern C, Jood K, Wallin A, Blennow K, Zetterberg H (2007). Kinesin gene variability may affect tau phosphorylation in early Alzheimer’s disease. Inj J Mol Med 20(2):233-9.

Carmine Belin A,. Björk B, Westerlund A, Galter D, Sydow O, Lind C, Pernold K, Rosvall L, Håkansson A, Winblad B, Nissbrandt H, Graff C, Olson L. Association study of two genetic variants in mitochondrial transcription factor A (TFAM) in Alzheimer’s and Parkinson’s disease. Neuroscience Letters 420(3):257-62 (2007)

Björk BF, Katzov H, Kehoe P, Fratiglioni L, Winblad B, Prince J A, Graff C. Positive association between risk for late-onset AD and variation in IDE Neurobiol Aging. 2007 Sep;28(9):1374-80.

Brynedal B, Duvefelt K, Jonasdottir G, Roos IM, Åkesson E, Palmgren J, Hillert J, HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS ONE 2007 Jul 25:2(7):e664.

Ferrer I, Armstrong J, Capellari S, Parchi P, Arzberger T, Bell J, Budka H, Strobel T, Giaccone G, Rossi G, Bogdanovic N, Fakai P, Schmitt A, Riederers P, Al-Sarraj S, Ravid R, Kretzschmar H (2007). Effects of formalin fixation, paraffin embedding and time of storage on DNA preservation in brain tissue: a BrainNet Europe study. Brain Pathol. 17(3):297-303.

Fogh I, Rijsdijk F, Andersen PM, Sham PC, Knight J, Neal B, McKenna-Yasek D, Silani V, Brown Jr RH, Powell JF, Al-Chalabi A. Age at onset in SOD1­-mediated amyotrophic lateral sclerosis (ALS) shows familiarity. Neurogenetics 2007;8:235-236.

Lundmark F, Salter H, Hillert J. An association study of two functional promotor polymorphisms in the myeloperoxidase (MPO) gene in multiple sclerosis. Mult Scler 2007 Jul:13(6):697-700.

Lundmark F, Duvefelt K, Hillert J. Genetic association analysis of the interleukin 7 gene (IL7) in multiple sclerosis. J Neuroimmunol. 2007 Dec;192(1-2):171-3.

Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallström E, Khademi M, Oturai A, Ryder LP, Saarela J, Harbo HF, Celius EG, Salter H, Olsson T, Hillert J. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet. 2007 Sep:39(9):1108-13.

Nilsson A, Eriksson M, Muly EC, Åkesson E, Samuelsson EB, Bogdanovic N, Benedikz E, Sundström E (2007). Analysis of NR3A receptor subunits in human native NMDA receptors. Brain Res. 1186:102-12.

O’Doherty C, Roos IM, Antiguedad A, Aransay AM, Hillert J, Vandenbroeck K. ITGA4 polymorphisms and susceptibility to multiple sclerosis. J Neuroimmunol. 2007 Sep;189(1-2):151-7.

Ostberg P, Crinelli RM, Danielsson R, Wahlund LO, Bogdanovic N, Fernaeus SE (2007) A temporal lobe factor in verb fluency. Cortex 43(5):607-15.

Romanita MO, Popescu BO, Winblad B, Bajenaru OA, Bogdanovic N. Occludin is overexpressed in Alzheimer’s disease and vascular dementia. J Cell Mol Med 2007;11(3):569-579

Samuelsen GB, Pakkenberg B, Bogdanovic N, Gundersen HJ, Larsen JF, Graem N, Laursen H (2007). Severe cell reduction in the future brain cortex in human growth-restricted fetuses and infants. Am J Obstet Gynecol. 197(1):56.e1-7.

Sandelin E, Nordlund A, Andersen PM, Marklund SL, Oliveberg M. ALS-associated SOD1 mutations preferentially reduce the proteins repulsive charge. J Biol Chem 2007;282:21230-21236.

Schymick J, Yang Y, Andersen PM, Vonsattel JP, Greenway M, Momeni P, Elder J,1, Chiò A, Restagno G, Robberecht W, Dahlberg C, Mukherjee O, Goate A, Graff-Radford N, Caselli R, Hutton M, Gass J, Cannon A, Rademakers J, Singleton A, Hardiman O, Rothstein J, Hardy J, Traynor B. Progranulin mutations and ALS or ALS-FTD phenotypes. J Neurol Neurosurg Psychiatry 2007;78:754-756.

Sjölander A, Minthon L, Bogdanovic N, Wallin A, Zetterberg H, Blennow K (2007). The PPAR-alpha gene in Alzheimer’s disease: Lack of replication of earlier association. Neurobiol Aging Sep 10.

Smestad CV, Brynedal B, Jonasdottir G, Lorentzen AR, Masterman T, Akesson E, Spurkland A, Lie BA, Palmgren J, Celius EG, Hillert J, Harbo HF. The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol. 2007 Aug;14(8):835-40.

Turner MR, Rabiner EA, Al-Chalabi A, Shaw CE, Brooks DJ, Leigh PN, Andersen PM. Cortical 5-HT1A receptor binding in patients with homozygous D90A SOD1 vs  sporadic ALS. Neurology 2007;68:1233-1235.

Turner MR, Hammers A, Al-Chalabi A, Shaw CE, Andersen PM, Brooks DJ, Leigh PN. [11C]-Cortical involvement in four cases of primary lateral sclerosis using [11C]-Flumazenil PET. J Neurol 2007;254:1033-1036.

Turner MR, Hammers A, Allsop J, Al-Chalabi A,,Shaw C, Brooks D, Leigh PN, Andersen PM. Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis. ALS 2007;8:343-347.

van Es MA, van Vught PW, Blauw HM, Franke L, Saris CG, Andersen PM, van den Bosch L, de Jong SW, Slot Rv, Birve A, Lemmens R, de Jong V, Baas F,  Schelhaas JH, Sleegers K, van Broeckhoven C, Wokke JH, Wijmenga C,Robberecht W, Veldink JH, Ophoff RA, van den Berg LH. Genome-wide association study of sporadic amyotrophic lateral sclerosis identifies ITPR2 as a susceptibility gene. Lancet Neurology 2007;6:869-877.

Zetterström P, Stewart HG, Bergemalm D, Jonsson A, Graffmo KS, Andersen PM, Brännström T, Oliveberg M, Marklund SL. Soluble misfolded subfractions of mutant superoxide dismutase 1s are enriched in spinal cords throughout life in transgenic murine ALS models. Proc Natl Acad Sci U S A. 2007;104:14157-62.

Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM. CSF Neurofilament light levels and APOE genotype in familial and sporadic amyotrophic lateral sclerosis. Eur J Neurol 2007;14:1329-1333.

Zetterberg M, Landgren S, Andersson ME, Palmér MS, Gustafson DR, Skoog I, Minton L, Thelle DS, Wallin A, Bogdanovic N, Andreasen N, Blennow K, Zetterberg H. Association of complement factor H Y402H gene polymorphism with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet. 2007 Dec 28.

Alafuzoff I, Arzberger T, Al-Sarraj S. Bodi I, Bogdanovic N, Braak H, Bugiani O, Del-Tredici K, Ferrer I, Gelpi E, Giaccone G, Graeber MB, Ince P, Kamphorst W, King A, Korkolopoulou P, Kovács GG, Larionov S, Meyronet D, Monoranu C, Parchi P, Patsouris E, Roggendorf W, Seilhean D, Tagliavini F, Stadelmann C, Streichenberger N, Thal DR Wharton SB, Kretschmar H. (2008). Staging of neurofibrillary pathology in Alzheimer’s disease: A study of the BrainNet Europe Consortium: Brain Pathol. 2008 Mar 26.

Alafuzoff I, Parkkinen L, Al-Sarraj S, Arzberger T, Bell J, Bodi I, Bogdanovic N, Budka H, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Kamphorst W, King A, Korkolopoulou P, Kovacs GG, Larionov S, Meyronet D, Monoranu C, Morris J, Parchi P, Patsouris E, Roggendorf W, Seilhean D, Streichenberger N, Thal DR, Krezschmar H; BrainNet Europe Consortium (2008). Assessment of alpha-synuclein pathology: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol 67(2):125-43.

Annerbrink K, Westberg L, Nilsson S, Rosmond R, Holm G, Eriksson E. COMT val158-met polymorphism is associated with abdominal obesity and blood presssure in men, 2008, Metabolism, 57 (5), 708-711.

Aoki M, Volkmann I, Tjernberg LO, Winblad B, Bogdanovic N. Amyloid beta-peptide levels in laser capture microdissected cornu ammonis 1 pyramidal neurons of Alzheimer’s brain. Neuroreport 2008 Jul; 16(7):603-11

Aulchenko YS, Hoppenbrouwers IA, Ramagopalan SV, Broer L, Jafari N, Hillert J, Link J, Lundström W, Greiner E, Dessa Sadovnick A, Goossens D, Broeckhoven CV, Del-Favero J, Ebers GC, Oostra BA, van Duijn CM, Hintzen RQ. Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis. Nat Genet 2008 Nov 9.

Basun H, Bogdanovic N, Ingelsson M, Almkvist O, Näslund J, Axelman K, Bird TD, Nochlin D, Schellenberg GD, Wahlund Lo, Lannfelt L. (2008). Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol 65(4):499-505.

Bell JE, Alafuzoff I, Al-Sarraj S, Arzberger T, Bogdanovic N, Budka H, Dexter DT, Falkai P, Ferrer I, Gelpi E, Gentleman SM, Giaccone G, Huitinga I, Ironside JW, Klioueva N, Kovacs GG, Meyronet D, Palkovits M, Parchi P, Patsouris E, Reynolds R, Riederer P, Roggendorf W, Seilhean D, chmitt A, Schmitz P, Streichenberger N, Schwalber A, Kretzschmar H. (2008). Management of a twenty-first century brain bank: experience in the BrainNet Europe Consortium. Acta Neuropathol 115(5):497-507.

Booth DR, Heard RN, Stewart GJ, Goris A, Dubosi R, Dubois B, Lorentzen AR, Celius EG, Harbo HF, Spurkland A, Olsson T, Kockum I, Link J, Hillert J et al. The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun 2008 Nov 6.

Broom WJ, Johnson DV, Auwarter KE, Iafrate AJ, Russ C, Al-Chalabi A, Sapp PC, McKenna-Yasek D, Andersen PM, Brown Jr, RH. SOD1A4V-meditated ALS: Absence of a closely linked modifier gene and origination in Asia. Neurosci Lett 2008;430:241-245.

Chiang H-H, Rosvall L, Brohede J, Axelman K, F Björk B, Nennesmo I, Robins T, Graff C. Progranulin mutation causes frontotemporal dementia in the Swedish Karolinska family. Alzh & Dementia 2008; 4(6):414-420

Cronin S, Greenway MJ, Andersen PM, Hardiman O. Screening of hypoxia-inducible genes in sporadic ALS. ALS 2008; 9:299-305.

Darmopil S, Petanjek Z, Mohammed AH, Bogdanovic N. Environmental enrichment alters dentate granule cell morphology in oldest-old rat. JCMM 2008, Oct, EPUB ahead of print.

Dufour E, Terzioglu M, Sterky FH, Sörensen L, Galter D, Olson L, Wilbertz J, Larsson NG. Age-associated mosaic respiratory chain deficiency causes transneuronal degeneration. Hum Mol Genet 2008; 17:1418-1426.

Eisen A, Mezei M, Stewart HG, Fabros M, Gibson G, Andersen PM. SOD1 gene mutations in ALS patients in British Columbia, Canada: Clinical features, neurophysiology and ethical issues in management. ALS 2008; 9:108-119.

Forsell C, Björk B F, Lilius L, Karin Axelman, Froelich Fabre S, Fratiglioni L, Winblad B, Graff C. Genetic Association to the amyloid plaque associated protein gene COL25A1 in Alzheimer’s disease. Neurobiol Aging 2008 May 21.

Håkansson A, Carmine Belin A, Stiller C,  Sydow O, Johnels B, Olson L, Holmberg B and Nissbrandt H. Investigation of genes related to familial forms of Parkinson’s disease – with focus on the Parkin gene. Parkinsonism and Related Disorders 2008; 14:520-522. .

Jonsson A, Bergemalm D, Andersen PM, Gredal O, Brännström T, Marklund SL. Inclusions of ALS-linked SOD in ventral horns, liver and kidney. Ann Neurol 2008; 63:671-675.

Kovacs GG, Alafuzoff I, Al-Sarraj S, Arzberger T, Bogdanovic N, Capellari S, Ferrer I, Gelpi E, Kövari V, Kretzschmar H, Nagy Z, Parchi P, Seilhean D, Soininen H, Troakes C, Budka H. Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord 2008; 26(4):343-350.

Kristjansdottir G, Sandling JK, Bonetti A, Roos IM, Milani L, wang C, Gustafsdottir SM, Sigurdsson S, Lundmark A, Tienari PJ, Koivisto K, Elovaara I, Pirttilä T, Reunanen M, Peltonen L, Saarela J, Hillert J, Olsson T, Landegren U, Alcina A, Fernández O, Leyva L, Guerrero M, Lucas M, Izquierdo G, Matesanz F, Syvänen AD. Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet. 2008 Jun;45(6):362-9.

Lambrechts D, Poesen K, Fernandez-Santiago R, Ammar Al-Chalabi A, Bo RD, Khan H, van Vught PWJ, Marklund SL, Brockington A, van Marion I, Shaw C, Ludolph AC, Leigh PN, Comi GC, Gasser T, Shaw PJ, Morrison KE, Andersen PM, van den Berg L, Thijs V, Siddique T, Robberecht W, Carmeliet P. Meta-analysis of VEGF variations in ALS: increased susceptibility in male carriers of the -2578 AA genotype. J Med Genet 2008.058222 (EPUB ahead of print).

Lorentzen AR, Smestad C, Lie BA, Oturai AB, Akesson E, Saarela J, Myhr KM, Vartdal F, Celius EG, Sörensen PS, Hillert J, Spurkland A, Harbo HF. The SH2D2A gene and susceptibility to multiple sclerosis. J Neuroimmunol 2008 Jul 15;197(2):152-8.

Mochel F, Knight MA, Tong W-H, Hernandez D, Ayyad K, Taivassalo T, Andersen PM, Singleton A, Rouault TA, Fischbeck KH, Haller RG. Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise intolerance. Am J Hum Genet 2008; 82:652-660.

Roos IM, Kockum I, Hillert J. The interleukin 23 receptor gene in multiple sclerosis: A case-control study. J Neuroimmunol. 2008 Feb;194(1-2):173-80.

Skoglund L, Viitanen M, Kalimo H, Lannfelt L, Eriksdotter Jönhagen M,  Ingelsson M, Glaser A, Herva R. The Tau S305S Mutation Causes Frontotemporal Dementia with Parkinsonism. Eur J Neur 2008, (in press).

Thangarajh M, Gomez-Rial J, Hedström AK, Hillert J, Alvarez-Cermeño JC, Masterman T, Villar LM. Lipid-specific immunoglobulin M in CSF predicts adverse longterm outcome in multiple sclerosis. Mult Scler 2008, Aug 28.

Valdmanis PN, Kabashi E, Dyck A, Hince P, Lee J, Dion P, D’Amour M, Bouchard J-P, Souchon F, Salachas F, Meininger V, Andersen PM, Camu W, Dupré N, Rouleau GA. Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec and Sweden. Neurology 2008; 71:514-520.

van de Giessen E, Fogh I, Gopinath S, Smith B, Hu X, Powell J, Andersen P, Nicholson G, Al Chalabi A, Shaw CE. Association study on glutathione S-transferase omega 1 and 2 and familial ALS. ALS 2008; 9:81-84.

van Es MA, van Vught PW, Blauw H, Franke L, Van Den Bosch L, de Jong SW, Vianney de Jong V, Baas F, van ’t Slot R, Lemmens R,  Schelhaas HJ, Birve A, Sleegers K, van Broeckhoven C, Schymick JC,  Traynor BJ, Wokke JH, Wijmenga C, Robberecht W, Andersen PM, Veldink JH, Ophoff RA, van den Berg LH. Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nat Genet 2008;40:29-31

Westerlund M, Ran C, Borgkvist A, Sterky FH, Lindqvist E, Lundströmer K, Pernold K, Brené S, Kallunki P, Fisone G, Olson L, Galter D. Lrrk2 and alpha-synuclein are co-regulated in rodent striatum. Mol Cell neurosci 2008; 39:586-591

Westerlund M, Belin AC, Olson L, Galter D. Expression of multidrug resistance 1 mRNA in human and rodent tissues: reduced levels in Parkinson patients. Cell Tissue Res 2008; 334:179-185.

Westerlund M, Belin AD, Anvret A. Hakansson A, Nissbrant H, Lind C, Sydow O, Olson L, Galter D. Cerebellar alpha-synuclein levels are decreased in Parkinson’s disease and do not correlate with SNCA polymorphisms associated with disease in a Swedish material. Faseb J 2008; 22:3509-3514.

Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM. Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis. J Neurol Sci 2008; 273:67-69.

Graff C. Ärftlighet vid Alzheimers sjukdom. Nordisk Geriatrik, Feb 1: 4-6 (2005)

Ekman S-E, Eriksdotter Jönhagen M, Fratiglioni L, Graff C, Jansson W, Robinson P, Tjernberg L, Wahlund L-O. Alzheimer. Karolinska Institutet University Press, April 2007. ISBN 978-91-85565-04-7

Graff C, Nordenskjöld M. Genetisk testning av riskalleler för vanliga sjukdomar.Läkartidningen 105(11) 812-814 (2008)

Belin AC, Galter D. S18Y, UCH-L1 and Parkinson’s disease. European Neurol 2009; 3(2):41

Bergman O, Håkansson A, Westberg L, Carmine Belin A, Sydow O, Olson L, Holmberg B, Eriksson E, Nissbrandt H. Do polymorphisms in transcription factors LMX1A and LMX1B influence the risk for Parkinson’s disease? J Neural Transm 2009; 116(3):333-338.

Bergman O, Håkansson A, Westberg L, Nordenström K, Carmine-Belin A, Sydow O, Olson L, Holmberg B, Eriksson E, Nissbrandt H. PITX3 polymorphism is associated with early onset Parkinson’s disease. Neurobiol Aging. EPUB ahead of print.

Blackinton J, Kumaran R, van der Brug MP, Ahmad R, Olson L, Galter D, Lees A, Bandopadhyay R, Cookson MR. Post-transcriptional regulation of mRNA associated with DJ-1 in sporadic Parkinsno disease. Neurosci Lett 2009; 452:8-11.

Blumen SC, Inzelberg R, Nisipeanu P, Carasso RL, Oved D, Eisenstein O, Drory VE, Bergström C, Andersen PM. Aggressive Familial ALS with unusual brain MRI and an A140A SOD1 gene mutation. ALS 2009, EPUB ahead of print.

Borg J, Henningsson S, Saijo T, Inoue M, Bah J, Westberg L, Lundberg J, Jovanovic H, Andrée B, Nordström AL, Halldin C, Eriksson E, Farde L. Serotonin transporter genotype is associated with cognitive performance but not regional 5-HT1A receptor binding in humans. Inj J Neuropsychopharm 2009; 12:783-192.

Brynedal B, Bomfim IL, Olsson T, Duvefelt K, Hillert J. Differential expression and genetic association of CD58 in Swedish multiple sclerosis patients. PNAS USA 2009 Jun9; 106(23):E58; author reply E59.

de Frias CM, Marklund P, Eriksson E, Larsson A, Öman L, Annerbrink K, Bäckman L, Nilsson L-G, Nyberg L: Influence of COMT gene polymorphisms on fMRI-assessed sustained and transient activity during a working memory task. J Cogn Neurosci 2009, EPUB ahead of print.

Evangelou E, Maraganore DM, Carmine Belin A, Olson L, Galter D et al. Non-replication of association for six polymorphisms from meta-analysis of genome-wide association studies of Parkinson’s disease: Large-scale collaborative study. Am J Med Genet B Neuropsychiatr Genet 2009 May 27. EPUB ahead of print.

Henningsson S, Borg J, Lundberg J, Bah J, Lindström M, Ryding E, Träskman-Bendz L, Farde L, Eriksson E. Genetic variation in BDNF is associated with serotonin transporter availability in humans. Biol Psychiatry 2009; 66:477-485.

Imrell K, Greiner E, Hillert J, Masterman T. HLA-DRB1*15 and cerebrospinal-fluid-specific oligoclonal immunoglobulin G bands lower age at attainment of important disease milestones in multiple sclerosis. J Neuroimmunol 2009 May 29; 210(1-2):128-130.

Kallio SP, Jakkula E, Purcell S, Suvela M, Koivisto K, Tienari PJ, Elovaara I, Pirttilä T, Reunanen M, Bronnikov D, Viander M, Meri S, Hillert J et al. Use of a genetic isolate to identify rare disease variants: C7 on 5p associated with MS. Hum Mol Genet 2009 Feb 16.

Kemppinen A, Suvela M, Tienari PJ, Elovaara I, Koivisto K, Pirttilä T, Reunanen M, Rautakorpi I, Hillert J et al. MYO9B polymorphisms in multiple sclerosis. Eur J Hum Genet 2009 Jan 14.

Martola J, Stawiarz L, Fredikson S, Hillert J, Bergstrom J, Flodmark O, Aspelin P, Kristoffersen Wiberg M. One-dimensional ratio measures of atrophy progression in multiple sclerosis as evaluated by longitudinal magnetic resonance imaging. Acta Radiol 2009 Jul; 28:1-9.

Niazi Shababi H, Westberg L, Melke J, Håkansson A, Carmine Belin A, Sydow O, Olson L, Holmberg B, Nissbrandt H. Cytochrome P450 2E1 gene polymorphisms/haplotypes and Parkinson’s disease in a Swedish population. J Neural Transm (in press).

Popescu BO, Toescu EC, Popescu LM, Bajenaru O, Muresanu DF, Schultzberg M, Bogdanovic N. Blood-brain barrier alterations in ageing and dementia. J Neurol Sci 2009; 283(1-2):99-106.

Prudencio M, Hart PJ, Borchelt DR, Andersen PM. Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease. Hum Mol Genet (in press).

Saeed M, Yang Y, Deng H-X, Hung WY, Siddique N, Dellefave L, Gellera C, Andersen PM, Siddique T. Age and founder effect of SOD1 A4V mutation causing ALS. Neurology 2009; 72:1634-1639.

Shababi HN, Westberg L, Melke J, Håkansson A, Carmine Belin A, Sydow O, Olson L, Holmberg B, Nissbrandt H. Cytochrome P450 2E1 gene polymorphisms/haplotypes and Parkinson’s disease in a Swedish population. J Neural Trans 2009; 116:567-573.

Stanton BR, Shinmar D, Turner MR, Williams VC, Williams SCR, Blain CRV, Giampietro VP, Catani M, Leigh PN, Andersen PM, Simmons A. Diffusion tensor imaging in sporadic and amilial (D90A SOD1) forms of Amyotrophic Lateral Sclerosis. Arch Neurol 2009; 66:109-115.

Synofzik M, Fernández-Santiago R, Maetzler W, Schöls L, Andersen PM. The human G93A SOD1 phenotype closely resembles sporadic ALS. J Neurol Neurosurg Psych (in press).

Welander H, Frånberg J, Graff C, Sundström E, Winblad B, Tjernberg L. Aß43 is more frequent than Aß40 in amyloid plaque cores from Alzheimer disease brains. J Neurochem 2009 Jul;110(2):697-706.

Westerlund M, Carmine Belin A, Anvret A, Håkansson A, Nissbrandt H, Lind C, Sydow O, Olson L, Galter D. Association of a polymorphism in the ABCB1 gene with Parkinson’s disease. Parkinsonism Relat Disord 2009; 15:422-424.

 

Biomarkörer

Heverin M, Meaney S, Lütjohann D, Diczfalusy U, Wahren J, Björkhem I. Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain and possible consequences for cerebral cholesterol homeostasis. J. Lipid Res. 46 (2005) 1047-1052.

Heverin M: Brain cholesterol metabolism: A study of mouse and man.  Academic Thesis, Karolinska Institutet, Stockholm 2005

Björkhem I, Heverin M, Leoni V, Meaney S, Diczfalusy U. Oxysterols and Alzheimer’s disease. Acta Neurol. Scand. 185 (2006) 43-49

Björkhem, I. Crossing the barrier. Oxysterols as cholesterol transporters and metabolic modulators in the brain.  J. Int. Med. 260 (2006) 493-508

Karrenbauer DV, Leoni V, Lim ET, Giovannoni G,  Ingle GT, Sastre-Garriga J, Thompson AJ, Rashid W, Davies G, Miller DH, Björkhem I, Masterman T. Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis. Clin.Neurol. Neurosurg. – 108 (2006) 456-460

Leoni V, Shaafati M, Salomon A, Kivipelto M, Björkhem I, Wahlund L-O. Are the CSF levels of 24S-hydroxycholesterol a suitable biomarker for mild cognitive impairment? Neurosci. Lett. 397 (2006) 83-87

Ohyama Y, Meaney S, Heverin M, Ekström L, Brafman A, Andersson A, Olin M, Eggertsen G, Diczfalusy U, Feinstein E, Björkhem I. Studies on the transpcriptional regulation of cholesterol 24-hydroxylase (CYP46A1): marked insensitivity towards different regulatory axes. J. Biol. Chem. 281 (2006) 3810-3820

Portelius E, Zetterberg H, Andreasson U, Brinkmalm G, Andreasen N, Wallin A, Westman-Brinkmalm A, Blennow K. An Alzheimer’s disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neurosci Lett. 2006;409:215-9.

Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res. 2006;5:1010-6.

Thelen KM, Rentsch KM, Gutteck U, Heverin M, Olin M, Andersson U, von Eckardstein A, Björkhem I, Lütjohann D. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J. Pharm. Exp. Ther. 316 (2006) 1146-1152

C Andersson, O Almkvist, P Engfeldt, M Lindau, SE Johansson,  K Blennow, M Eriksdotter-Jönhagen. Differential CSF biomarker levels in APOE ε4 positive and negative patients with memory impairment. Dement Cogn Disord 23:87-95, 2007.

Björkhem I. Rediscovery of cerebrosterol. Lipids 428 (2007) 5-14

Björkhem I, Meaney S, Heverin M, Andersson U, Axelson M, Panzenboeck U, and Sattler W. Role of oxysterols and cholestenoic acid in a crosstalk between the brain and the liver. Proceedings of the XIX International Bile Acid Meeting: Biological Actions and Clinical Relevance, Kluwer Academic Press 2007; pp 8-10.

Björkhem I, Meaney S, Heverin M, Panzenboeck U, Andersson U, Sattler W, Pikuleva I, Ohyama Y, Wahren J. Role of Cytochrome P-450 species in the brain. Proceedings of the 15th International Conference on Cytochrome P-450: Biochemistry, Biophysics and Functional Genomics. Medimond International Proceedings 2007; pp 9-15

Bretillon L, Diczfalusy U, Björkhem I, Maire MA, Martine L, Joffre C, Acar N, Bron A, Creuzot.Garcher, C. Curr. Eye Res. 32 (2007) 361-366

Famer D, Meaney S, Mousavi M, Nordberg A, Björkhem I, Crisby M. Regulation of a-and b-secretase activity by oxysterols: Cerebrosterol stimulates processing of APP via the a-secretase pathway. Biochem. Biophys. Res. Commun.  359 (2007) 46-50

Heverin M, Meaney S, Brafman A, Shafir M, Olin M, Shafaari M, vonBahr S, Larsson L, Lövgren-Sandblom A, Diczfalusy U, Parini P, Feinstein E, Björkhem I. Studies on the cholesterol-free mous. Arterioscl Thromb Vasc Bil. 27 (2007) 2191-2197.

Mattsson N, Rüetschi U, Podust VN, Stridsberg M, Li S, Andersen O, Haghighi S, Blennow K, Zetterberg H. Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. J Neurochem 2007; 103:1932-1939.

Meaney S, Heverin M, Panzenboeck U, Ekström L, Axelson M, Andersson U, Diczfalusy U, Pikuleva I, Wahren J, Björkhem I. Novel route for the elimination of brain oxysterols across the blood-brain barrier: Conversion into 27-hydroxycholesterol via 7-alpha-hydroxy-3-oxo-4-cholestenoic acid. J. Lipid Res. 48 (2007) 944-951

Murphy, C: Studies on the regulatory role of cholesterol and bile acids. Academic Thesis, Karolinska Institutet, Stockholm 2007

Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, Blennow K, Westman-Brinkmalm A. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res. 2007;6:4433-9.

Shaafati M, Solomon A, Kivipelto M, Björkhem I, Leoni V. Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders Neurosci Lett 2007;425:78-82.

Valenza M, Carroll JB, Leoni V, Bertram LN, Björkhem I, Singaraja RR, DiDonato S, Lutjohann D, Hayden MR and Catteano E. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Hum Mol. Genet. 2007;16:2187-2198.

Valenza M, Leoni V, Tarditi A, Mariotti C, Björkhem I, DiDonato S, Catteano E. Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington’s disease. Eurobiol Dis 28 (2007) 133-142.

Zetterberg M, Landgren S, Andersson ME, Palmér MS, Gustafson DR, Skoog I, Minthon L, Thelle DS, Wallin A, Bogdanovic N, Andreasen N, Blennow K, Zetterberg H. Association of complement factor H Y402H gene polymorphism with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet. 2007 Dec 28

Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerström C, Syversen S, Mattsson UB, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman A, Blennow K, Wallin A. Intra-individual stability of CSF biomarkers for Alzheimer’s disease over two years. J Alzheimers Dis. 2007;12:255-60.

C Andersson, K Blennow, O Almkvist, N Andreasen, P Engfeldt, SE Johansson, M Lindau, M Eriksdotter-Jönhagen. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging, 2008;29:1466-1473.

Andreasen N, Zetterberg H. Amyloid-related biomarkers for Alzheimer’s disease. Current Medicinal Chemistry. 2008, (in press).

Buchhave P, Stormrud E, Warkentin S, Blennow K, Minthon L, Hansson O. Cube copying test in combination with rCBF or CSF Aß42 predicts development of Alzheimer’s disease. Dement Geriatr Cogn Disord 2008; 25:544-552.

Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K. Evaluation of plasma Aß40 and Aß42 as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging 2008. EPUB ahead of print.

Leoni V, Mariotti C, Tabrizi SJ, Valenza M, Wild EJ, Henley S, Hobbs NZ, Mandelli ML, Grisoli M, Björkhem I, Cattaneo E, Di Donato S. Plasma 24S-hydroxycholesterol and caudate MRI in premanifest and early Huntington’s disease. Brain 2008 – (in press).

Mast N, White MA, Björkhem I, Johnson EF, Stout C, Pikuleva I. Crystal structure of substrate-bound and substrate-free cytochrome P450 46A1 – the principal cholesterol-hydroxylase in th brain. Proc Natl Acad Sci. 105(2008) 9546-9551.

Mattson N, Rüetschi U, Pijnenburg YAL, Blankenstein MA, Podust VN, Li s, Fagerberg I, Rosengren L, Blennow K, Zetterberg H. Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia. Mol Med Reports 2008; 1:757-761.

Nordlund A, Rolstad S, Klang O, Lind K, Pedersen M, Blennow K, Edman A, Hansen S, Wallin A. Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI. J Int Neuropcyshol Soc 2008; 14:582-590.

Portelius E, Hansson S, Tran AJ, Zetterberg H, Grognet P, Vanmechelen E, Nordhoff E, Blennow K, Gobom J. Characterization of tau in cerebrospinal fluid using mass spectrometry. J Proteome Res 2008;7:2114-2120.

Stomrud E, Hansson O, Minthon L, Blennow K, Rosén I, Londos E. Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years. Neurobiol Aging 2008. EPUB ahead of print.

White MA, Mast N, Björkhem I, Johnson EF, Stout D, Pikuleva I. Structure of cytochrome P450 46A1 solved by use of complementary cation and anion heavy atom salt derivatives. Acta Crystallogr. 64 (2008) 487-495.

Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, Simon AJ, Blennow K. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 2008;65:1102-1107

Zetterberg H, Rüetschi U, Portelius E, Brinkmalm G, Andreasson U, Blennow K, Brinkmalm A. Clinical proteomics in neurodegenerative disorders. Acta Neurol Scand. 2008, (in press).

Acimovic J, Lövgren-Sandblom A, Monostery K, Rozman D, Golicnik M, Lutjohann D, Björkhem I. Combined gas chromatographic – mass spectrometric analysis of cholesterol precursors and plant sterols in cultured cells. J Chromatogr B 2009; 877:2081-2086.

Björkhem I. Are side-chain oxidized oxysterols regulators also in vivo? J Lipid Res 2009; 50:213-218.

Björkhem I, Leoni V, Cedazo-Minguez A, Meaney S. Oxysterols and neurodegeneration. Mol Aspects of Medicine 2009; 30: 171-179.

Bojanic DD, Gale GD, Smith DJ, Bok D, Nusinowitz S, Lövgren-Sandblom A, Björkhem I, Edwards P. Differential expression and function of ABCG1 and ABCG4 during development and aging. J Lipid Res 2009 (in press).

Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O. Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging 2008, in press.

Buchhave P, Janciauskiene S, Zetterberg H, Blennow K, Minthon L, Hansson O. Elevated plasma levels of soluble CD40 in incipient Alzheimer´s disease. Neurosci Lett 2009;450:56-59.

Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, Minthon L, Hansson O. Longitudinal study of CSF biomarkers in patients with Alzheimer’s disease. PLoS One 2009;4:e6294.

Darreh-Shori T, Modiri M, Blennow K, Baza S, Kamil C, Ahmed H, Andreasen N, Nordberg A. The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobiol Aging 2009, in press.

Gorham P, Bark N, Meaney S, Björkhem I, Crisby M. Platlet alpha and beta-secretase activities are not significantly affected by dementia or mild cognitive impairment in Swedish patients. Curr Alzh Res 2009 (in press).

Hansson SF, Andréasson U, Wall M, Skoog I, Andreasen N, Wallin A, Zetterberg H, Blemmow K. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer’s disease patients. J Alzh Dis 2009; 16:389-397.

Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer’s disease. Neurobiol Aging 2009; 30:165-173.

Mattsson N, Yaong M, Rosengren L, Blennow K, Månsson JE, Andersen O, Zetterberg H, Haghighi S, Zho I, Pratico D. Elevated cerebrospinal fluid levels of prostaglandin E2 and 15-(S)-hydroxyeicosatetraenoic acid in multiple sclerosis. J Intern Med 2009;265:459-464.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, M van der Flier W, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Eriksdotter Jönhagen M, Minthon L, Winblad B, Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385-393.

Portelius E, Brinkmalm G, Tran AJ, Zetterberg H, Westman-Brinkmalm A, Blennow K. Identification of novel APP/Aß isoforms in human cerebrospinal fluid. Neurodegener Dis 2009; 6:87-94.

Portelius E, Brinkmalm G, Tran A, Andreasson U, Zetterberg H, Westman-Brinkmalm A, Blennow K, Öhrfelt A. Identification and pathological evaluation of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid. Exp Neurol 2009, in press.

Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, Westman-Brinkmalm A, Zetterberg H, Simon AJ, Blennow K. A novel pathway for amyloid precursor protein processing. Neurobiology of Aging 2009, in press.

Shafaati M, O’Driscoll R, Björkhem I, Meaney S. Transcriptional regulation of cholesterol 24S-hydroxylase by histone deacetylase inhibitors. Biochem Biophys Res Commun 2009; 378:689-694.

Shafaati M, Mast N, Beck O, Nayef R, Heo G, Björkmeh-Bergman L, Lutjohann D, Björkhem I, Pikuleva I. The antifungeal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase (CYP46A1) in vitro and in vivo. J Lipid Res 2009 (in press).

Simonsen A.H, McGuire J, Podust V.N, Davies H, Minthon L, Skoog I,  Andreasen N, Wallin A, Waldemar G, Blennow K. Identification of a Novel Panel of Cerebrospinal Fluid Biomarkers for Early Stage Alzheimer’s Disease. Neurobiol Aging, (in press).

Sjölander A, Minthon L, Bogdanovic N, Wallin A, Zetterberg H, Blennow K. The PPAR-alpha gene in Alzheimer’s disease: lack of replication of earlier association. Neurobiol Aging 2009; 30(4):666-668.

Solomon A, Leoni V, Kivipelto M, Besga A, Öksengård AR, Julin P, Svensson L, Wahlund LO, Andreasen N, Winblad B, Soininen H, Björkhem I. Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer’s disease. Neurosci Lett 2009; 462:89-93.

Stomrud E, Hansson O, Blennow K, Minthon L, Londos E. Longitudinal CSF biomarkers correlate with cognitive decline in healthy elderly. Arch Neurol 2009, in press.

Wallin ÅK, Hansson O, Blennow K, Londos E, Minthon L. Can CSF biomarkers or pre-treatment progression rate predict response in cholinesterase inhibitor treatment in Alzheimer’s disease? Int J Geriatr Psychiatry 2009;24:638-647.

Öhrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, Blennow K, Zetterberg H. Cerebrospinal fluid α-synuclein in neurodegenerative disorders – a marker of synapse loss?Neurosci Lett 2009;450:332-335.

 

Hjärnavbildning

Blomquist G, Engler H, Nordberg A, Ringheim A, Wall A, Forsberg A, Estrada S, Frändberg G, Antoni G, Långström B. Unidirectional influx and net accumulation of PIB. The open Neuroimaging journal 2008; 2:114-125.

Looi JCL, Lindberg O, Zandbelt BB, Ostberg P, Andersen C, Botes L, Svensson L, Wahlund LO.Am J Neuroragiology 2008; 29(8):1537-1543.

Oberg J, Spenger C, Wang FH, Andersson A, Westman E, Skoglund P, Sunnemark D, Norinder U, Klason T, Wahlund LO, Lindberg M. Age-related changes in brain metabolites observed by 1H MRS in APP/PS1 mice. Neurobiol Aging 2008 Sep; 29(9):1423-1433.

Forsberg A, Almkvist O, Engler H, Wall A, Långström B, Nordberg A. High PIB retention in Alzheimer’s disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzh Res 2009 (in press).

Kadir A, Nordberg A. Novel target probes for imaging of neurodegenerative disorders related to dementia. J Nucl Med 2009 (in press).

Lindberg O, Ostberg P, Zandbelt BB, Oberg J, Zhang Y, Andersen C, Looi JCL, Bogdanovic N, Wahlund LO. Cortical morphometric subclassification of frontotemporal lobar degeneration. Am J Neuroradiology 2009; 30(6):1233-1239.

Liu Y, Paajanen T, Zhang Y, Westman E, Wahlund LO, Simmons A, Tunnard C, Sobow T, Mecocci P, Tsolaki M, Vellas B, Muehlboeck S, Evans A, Spenger C,  Lovestone S, Soininen H; for the AddNeuroMed Consortium. Combination analysis of neuropsychological tests and structural MRI measures in differentiating AD, MCI and control groups – The AddNeuroMed study. Neurobiol Aging 2009 Aug 13. EPUB ahead of print.

Looi JCL, Maller JJ, Pagani M, Hogberg G, Lindberg O, Liberg B, Botes L, Engman EL, Zhang Y, Svensson L, Wahlund LO. Caudate volumes in public transportation workers exposed to trauma in the Stockholm train system. Psychiatr Res NeuroImaging 2009; 171(2):138-143.

Långström B, Grahnen A, Hartvig Honoré P, Borlak J, Bergström M, Nielsen B, Vanderheyden J-L, Watanabe Y, Josephsson R, Heilund-Carlsen PF, Schwagger M, Larson SM, Goldenberg DM, Melzer A, Engler H, Hicks R, Sundin A, Seppänen M, Hedenstierna G, Nordberg A, Brooks D. The risk of exaggerated risk aversion – a life and death struggle for molecular imaging. Eur J Nucl Med Mol Imaging 2009 (in press).

Nordberg A. The future: New methods of imaging exploration in Alzheimer’s disease. Front Neurol Neurosci 2009; 24:47-53.

Nordberg A. Molecular imaging markers in clinical trials in Alzheimer’s disease. JNHA 2009; 13:346-347.

Nordberg A. Amyloid imaging in early detection of Alzheimer’s disease. Neurodegen dis 2009 (in press).

Nordberg A, Rinne J, Kadir A, Långström B. PET imaging in Alzheimer’s disease. Nature reviews in Neurol (in press).

Schöll M, Almkvist O, Axelman K, Stefanova E, Wall A, Westman E, Långström B, Lannfelt L, Graff C, Nordberg A. Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol Aging 2009 (in press).

Simmons A, Westman E, Muelboeck S, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Wahlund L-O, Soininen H, Lovestone S, Evans A, Spenger C for the AddNeuroMed consortium. MRI measures of Alzheimer’s disease and the AddNeuroMed study. Annals NYAS (in press).

Svedberg M, Hall H, Hellström-Lindahl E, Estrada S, Guan Z, Nordberg A, Långström B. 11CPIB-amyloid binding and levels of Aß40 and Aß42 in postmortem brain tissue from Alzheimer patients. Neurochem Int 2009 May-Jun; 54(5-6):347-357.

Westman E, Spenger C, Oberg J, Reyer H, Pahnke J, Wahlund LO. In vivo 1H-magnetic resonance spectroscopy can detect metabolic changes in APP/PS1 mice after donepezil treatment. BMC Neurosci 2009 Apr 7; 10:33.

 

Klinisk forskning

Francis PT, Nordberg A, Arnold SE. A preclinical view of cholineasterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer’s disease? Trends in Pharmacological Science 2005;26:104-11.

Olin K, Eriksdotter Jönhagen M, Jansson A, Herrington MK,  Kristiansson M, Permert J. Postoperative delirium is a major cause of morbidity in elderly patients after abdominal surgery and is associated with intraoperative blood loss. British J Surgery. BJS 92 (12), 1559-1564, 2005

Santos, FS, Wahlund LO, Varli F, Eriksdotter Jönhagen M. Incidence and clinical features of postoperative delirium in elderly patients treated for hip fractures. Dement Geriatr Cogn Disord, 20: 231-237, 2005.Darreh-Shori T, Brimijoin S, Kadir A, Almkvist O, Nordberg A. Differential CSF butytylcholinesterase levels in Alzheimer’s disease patients with the ApoE e4 allele, in relation to cognitive function and cerebral glucose metabolism. Neurobiol Dis 24:326-333, 2006.

Darreh-Shori T, Meurling L, Pettersson T, Hugosson K, Hellström-Lindahl E, Andreasen N, Minthon L, Nordberg A. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer’s disease following chronic donepezil treatment. J Neural Transmission 113:1791-1801. 2006

Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Långström B, Nordberg A. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 129;2856-66, 2006.

Freund Levi, Eriksdotter-Jönhagen M,  Cederholm T, Basun H, Faxén Irving G,  Garlind A, Vedin I, Vessby B, Wahlund L-O, Palmblad J. Omega-3 fatty acid treatment of 174 patients with mild to moderate Alzheimer’s disease (OmegAD): a randomized double-blind trial. Arch Neurol 63: 1402-1408, 2006.

Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierny MC, Whitehouse P, Winblad B. Int Psychoger Assoc Expert Conf on mild cognitive impairment. Lancet 2006 Apr 15, 367(9518): 1262-70.

Jelic V, Kivipelto M, Winblad B. Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psych 2006 Apr;77(4):429-39.

Kadir A, Almkvist O, Wall A, Långström B, Nordberg A. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer’s disease.Psychopharmacology 188:509-520, 2006.

Nordberg A, Eriksdotter-Jönhagen M, Garlind A, Grut M, Freund-Levi Y, Cornelius C, Ekström A, Fastbom J, Sedvall M, Viitanen M. Värt ge symptomlindrande läkemedel vid Alzheimers sjukdom. Klinisk översikt. Läkartidningen 6:369-371, 2006.

Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord  20; Suppl 1, pp 12-18, 2006.

Nordberg A. Emerging biology of the cholinergic system across the spectrum of Alzheimer’s disease. Int Psychogeriatrics 1:S3-S16,2006.

Nordberg A. Positron Emission Tomography. In: Clinical diagnosis and Management of AD. Chapter 8 Functional brain imaging. Gauthier S (ed). Informa Healthcare, UK, 2006.

Nordberg, A. Visualization of nicotinic and muscarinic receptors in brain by positron emission tomography. In: The Brain Cholinergic System in Health and Disease. Giacobini E, Pepeu G (eds), pp 181-190, Informa Healthcare Ltd, UK, 2006.

Stefanova E, Wall A, Almkvist O, Nilsson A, Forsberg A, Långström B, Nordberg A. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer´s disease. J Neural Transm 113:205-218, 2006.

Williams BJ, Eriksdotter-Jonhagen M, Granholm A-C, Nerve growth factor in and pathogenesis of Alzheimer´s disease. Progress in Neurobiol. 80:114-128, 2006

Winblad B, Kilander L, Eriksson S, Minthon L, Båtsman S, Wetterholm AL, Jansson-Blixt C, Haglund A. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006 Apr; 367(9516):1057-65.

Cummings J, Winblad B. A rivastigmine patch for the treatment of Alzheimer’s disease and Parkinsons’s disease dementia. Expert Rev. Neurotherapeutics 2007 Nov;7(11): 1457-63.

Engler H, Santillo A, Lindau M, Savitcheva I, Nordberg A, Lannfelt L, Långström B, Kilander L. In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med and Molec Imaging 36:100-106, 2007.

Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, Ser del T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R. Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007 Jun;6(6):501-12

Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Långström B, Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiology of Aging, 2007, May 10.

Kadir A, Darreh-Shori T, Almkvist O, Wall A, Långström B, Nordberg A. Changes in brain (11C)-nicotine binding sites in patients with mild Alzheimer’s disease following rivastigmine treatment as assessed by PET. Psychopharmacology (Berl) 191:1005-1014, 2007.

Nordberg A. Amyloid imaging in Alzheimer’s disease. Curr Opinion in Neurology, 20:398-402, 2007.

Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, Scheltens P, Tariska P, Winblad B. EFNS recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007 Jan;14(1):e1-26.

Wallin Å K, Andreasen N, Eriksson S,  Båtsman S, Näsman B, Ekdahl A, Kilander L, Grut M, Rydén M, Wallin A, Jonsson M, Olofsson H, Wattmo C, Eriksdotter Jönhagen M and Minthon L Three-year outcome of Donepezil treatment in 435 patients with Alzheimer’s disease in a routine clinical setting – first results from the Swedish Alzheimer Treatment Study Group (SATS). Dement Cogn Disord  23(3):150-60 2007.

Veliz-Reissmuller G, Agüero Torres H, van der Linden L, Lindblom D, Eriksdotter Jönhagen M. Preoperative mild cognitive dysfunction predicts risk for postoperative delirium after elective cardiac surgery. Aging Clin and Exp Res. 19:172-177, 2007

Winblad B, Grossberg G, Frolich L, Farlow M, Sechner S, Nagel J, Lane R. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin parch for Alzheimer disease. Neurology 2007 Jul 24;69(4 suppl 1):S14-22.

Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R. A six-month’ double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007 May;22(5):456-67.

Winblad B, Kawata AK, Beusterien KM, Thomas SK, Wimo A, Lane R, Fillit H, Blesa R. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer’s disease. Int J Ger Psych 2007;22:485-91

Winblad B, Jelic V, Kershaw P, Amatniek J. Effects of statins on cognitive function in patients with Alzheimer’s disease in galantamine clinical trials. Drugs Aging 2007;24(1):57-61.

Darreh-Shori T, Kadir A, Almkvist O, Grut M, Wall A, Blomquist G, Eriksson B, Langstrom B, Nordberg A. Inhibition of acetylcholinesterase in CSF versus brain assessed by (11)C-PMP PET in AD patients treated with galantamine. Neurobiol Aging, 29:168-184, 2008.

Freund-Levi Y, Basun H, Cederholm T, Faxén-Irving G, Garlind A, Grut M, Vedin I, Palmblad J, Wahlund  L-O, Eriksdotter-Jönhagen M. Omega-3 supplementation in mild to moderate Alzheimer’s disease: effects on neuropsychiatric symptoms. Int J Ger Psych 23:161-169, 2008.

Johansson A, Savitcheva I, Forsberg A, Engler H, Långström B, Nordberg A, Askmark H. 11C-PIB-imaging in patients with Parkinson’s disease. Parkinsonism and related disorders, 14:345-347, 2008.

Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, Hagman G, Lärksäter M, Winblad B, Zetterberg H, Blennow K, Långström B, Nordberg A. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer’s disease. Annals Neurol 2008:63:621-631.

Kadir A, Darreh-Shori T, Almkvist O, Wall A, Grut M, Strandberg B, Ringheim A, Eriksson B, Blomquist G, Långström B, Nordberg A. PET imaging of the in vivo acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD: Neurobiology of Aging. 8:1204-1217, 2008

Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A, Darreh-Shori T, Soininen H, Pirttilä T, Farlow MR, Sfikas N, Baillard C, Greig NH. Synergistic effect of apolipoprotein E e4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer’s disease. Pharmacogenetics and Genomics 2008:18:289-298.

Nordberg A. Amyloid imaging in vivo: current achievement and future prospects. Eur J Nucl Med Mol Imaging 2008, Suppl 1:46-50.

Nordberg A. Amyloid imaging in Alzheimer’s disease. Neuropsychologia 2008:46:1636-1641.

Vedin I, Cederholm T, Freund Levi Y, Basun H, Garlind A, Faxén Irving G, Eriksdotter Jönhagen M, Vessby B, Wahlund LO and Palmblad J  Effects of a DHA based w3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes. The OmegAD study. JACN, In press 2008.

Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ, Wang D, Brashear HR, Nye JS; The GAL-INT-11/18 study group. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008 May 27;70(22):2024-35.

Winblad B, Black S, Homma A, Schwam EM, Moline M, Yu Y, Perdomo CA, Swartz J, Albert K. Donepezil treatment in severe Alzheimer disease: a pooled analysis of three clinical trials. Am J Geriatr Psychiatry, 2008.

Darreh-Shori T, Modiri N, Blennow K, Baza S, Kamil C, Ahmed H, Andreasen N, Nordberg A. The apolipoprotein E e4 allele has a pathological role in AD through high protein expression and interaction with butyrylcholinesterase. Neurobiol Aging

Ferris S, Nordberg A, Soininen H, Darreh-Shori T, Lane R. Progression from mild cognitive impairment disease: effect of sex, butyrylcholinesterase genotype and rivastigmine treatment. Pharmacogenetics and Genomics 2009; 10:635-646.

Nordberg A, Darreh-Shori T, Pesking E, Soininen H, Mousavi M, Eagle G, Lane R. Different cholineasterase inhibitor effects on CSF cholinesterases in Alheimer patients. Curr Alzh Res 2009; 6:4-14.

Persson C M, Wallin A K, Levander S & Minthon L. Changes in cognitive domains during three years in patients with Alzheimer’s disease treated with donepezil. BMC Neurology, 2009 Feb 10;9:7.

Pesking E, Nordberg A, Darreh-Shori T, Soininen H. Safety of lumbar puncture in patients with Alzheimer’s disease. Curr Alzh Res 2009; 6:290-292.

 

Epidemiologi

Mielke MM, Zandi PP, Sjögren M, Gustafson D, Östling S, Steen B, Skoog I. High total cholesterol levels in late-life associated with a reduced risk of dementia. Neurology 2005;64:1689-95.

Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005;4:487-99.

Rovio S, Kareholt I, Helkala EL, Viitanen M, Winblad B, Tuomilehto J, Soininen H, Nissinen A, Kivipelto M. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer’s disease. Lancet Neurology 2005 Nov; 4(11):705-11

Sacuiu S, Sjögren M, Gustafson D, Skoog I. Prodromal cognitive signs of dementia in 85-year-olds using four sources of information. Neurology 2005;65:1894-900.

Guo X, Pantoni L, Simoni M, Gustafson D, Bengtsson C, Palmertz B, Skoog I. Midlife respiratory function related to white matter lesions and lacunar infarcts in late life: The Prospective Population Study of Women in Gothenburg, Sweden. Stroke 2006;37:1658-62.

Henningsson S, Annerbrink K, Olsson M, Allgulander C, Andersch S, Sjödin I, Gustafson D, Skoog I, Norrback K, Adolfsson R, Eriksson E, Westberg L.  The Arg441His polymorphism in the tryptophan hydroxylase 2 gene in Sweden. Am J Med Genet B Neuropsychiatr Genet. 2006;144B:816-817

Jonsson L, Andreasen N, Kilander L, Soininen H, Waldemar G, Nygaard H, Winblad B, Jonhagen ME, Hallikainen M, Wimo A. Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord 2006 Jan-Mar;20(1):49-55

Mitnitski A, Skoog I,  Song X, Waern M, Ostling S,  Sundh V, Steen B, Rockwood K. A vascular risk factor index in relation to mortality and incident dementia. Eur J Neurol 2006;13:514-21.

Mielke MM, Zandi PP, Blennow K, Gustafson D, Sjögren M, Rosengren L, Skoog I.  Low Serum Potassium in Mid Life Associated with Decreased Cerebrospinal Fluid Abeta42 in Late Life. Alzheimer Dis Assoc Disord 2006;20:30-36.

Qiu C, Winblad B, Fratigliono L. Cerebrovascular diseae, APOE epsilon4 allele and cognitive decline in a cognitively normal population. Neurol Res 2006 Sep; 28(6):650-6.

De Ronchi D, Palmer K, Pioggiosi P, Atti AR, Berardi D, Ferrari B, Dalmonte E, Fratiglioni L. The combined effect of age, education and stroke on dementia and cognitive impairment no dementia (CIND) in the elderly. Dement Geriatr Cogn Disord 2007: 24(4);266-273

Fratiglioni L, Winblad B, Strauss EV. Prevention of Alzheimer’s disease and dementia. Major findings from the Kungsholmen project. Physiol Behav 2007 Sep 10;92(102:98-104.

Gudmundsson P, Skoog I, Waern M, Blennow K, Palsson S, Rosengren L, Gustafson D. The Relationship Between Cerebrospinal Fluid Biomarkers and Depression in Elderly Women. Am. J. Geriatr. Psychiatry 2007;15 832-838.

Guo X, Waern M, Sjögren K, Lissner L, Bengtsson C, Björkelund C, Östling S, Gustafson D,  Skoog I. Midlife Lung Function and Incidence of Alzheimer’s disease: a 29-year Longitudinal Study in Women. Neurobiol Aging 2007;28:343-50.

Gustafson D, Skoog I, Rosengren L, Zetterberg H, Blennow K. Ab42 and T-tau in cerebrospinal fluid predict cognitive decline and dementia in a population-based sample Cerebrospinal fluid Ab42 concentration may predict cognitive decline in elderly women. J Neurol Neurosurg Psychiatry 2007;78:461-4

Gustafson D, Karlsson C, Skoog I, Rosengren L, Lissner L, Blennow K.  Mid-life adiposity factors relate to blood brain barrier integrity in late-life. J Intern Med. 2007;262:643-50

Monastero R, Palmer K, Qui C, Winblad B, Fratiglioni L. Heterogeneity in risk factors for CIND – Population-based longitudinal study from the Kungsholmen project. Am J Geriatr Psychiatry 2007:15;60-69.

Ostling, S. Pálsson, S. Skoog, I. The incidence of first-onset psychotic symptoms and paranoid ideation in a representive population sample followed from age 70 to 90 years. Relation to mortality and later development of dementia.  Int J Geriatr Psychiatry 2007;22:520-8

Palmer K, Berger AK, Monastero R, Winblad B, Bäckman L, Fratiglioni L. Predictors of progression from Mild Cognitive Impairment to Alzheimer’s disease. Neurology 2007: 68(19);1596-1602

Wancata J, Börjesson-Hansson A, Östling S, Sjögren K, Skoog I. Diagnostic criteria influence dementia prevalence. Am J Geriatr Psychiatry 2007;15:1034-45.

Xu WL, Qiu CX, Winblad B, Fratiglioni L. The effect of borderline diabetes mellitus on the risk of dementia and Alzheimer disease. Diabetes 2007:56;211-216.

 

Neurospykologi

Andel R, Crowe M, Pedersen NL, Fratigli9oni L, Johansson B, Gatz M. Physical exercise at midlife and risk of dementia three decades later: a population-based study of Swedish twins. J Gerontol Biol Sci Med Sci 2008;63:62-66.

Atti AR, Palmer K, Volpato S, Winblad B, De Ronchi D, Fratiglioni L. Late-life body mass index and dementia incidence: Nine-year follow-up from the Kungsholmen project. J Am Geriatr Soc 2008;56:111-116

Caracciolo B, Palmer K, Monastero R, Bäckman L, Winblad B, Fratiglioni L. Occurrence of cognitive impairment and dementia in the community: a 9-year long prospective study. Neurology 2008 Jan 9

Duberstein PR, Palsson SP, Waern M, Skoog I. Personality and risk for depression in a birth cohort of 70-year-olds followed for 15 years. Psychol Medicine 2008; 38:663-671.

Edin Zylberstein D, Skoog I, Björkelund C, Guo X, Hultén B, Andreasson L-A, Palmertz B, Thelle DS, Lissner L. Homocysteine levels and lacunar brain infarcts in elderly women. The prospective population study of women in Gothenburg. J Am Geiatr Soc 2008;56:1087-91.

Eriksson UK, Gatz M, Dickman PW, Fratiglioni L, Pedersen NL. Asthma, eczema, rhinitis and the risk for dementia. Dement Geriatr Cogn 2008;25:148-156

Gatz M, Mortimer JA, Fratiglioni L, Johanson B, Berg S, Reynolds C, Pedersen NL. Potentially modifiable risk factors for dementia in identical twins. Alzheimers & Dementia 2008, (in press).

Kivipelto M, Rovio S, Ngandu T, Kåreholt I, Eskelinen M, Winblad B, Hachinski V, Cedazo-Minguez A, Soininen H, Tuomilehto J, Nissinen A. Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: A population-based study. J Cell Mol Med 2008 Mar 4.

Marengoni A, Winblad B, Karp A, Fratiglioni L. Prevalence of chronic diseases and multimorbidity among the elderly population in Sweden. Am J Public Health 2008 Jul; 98(7):11998-1200.

Mehlig K, Skoog I, Guo X, Schütze M, Gustafson D, Waern M, Östling S, Björkelund C, Lissner L. Alcoholic beverages and incidence of dementia: 34-year follow-up of the prospective population study of women in Goteborg. Am J Epidemiology 2008;167:684-91

Palmer K, Bäckman L, Winblad B, Fratiglioni L. Early symptoms and signs of cognitive deficits might not always be detectable in persons who develop Alzheimer’s disease. Int Psychogeriatrics 2008;20(2):252-258

Palmer K, Bäckman L, Winblad B, Fratiglioni L. Mild Cognitive Impairment in the general population: Occurrence and progression to Alzheimer’s disease. Am J Geriatr Psychiatry 2008.

Palmer K, Berger A-k, Monastero R, Winblad B, Bäckman L, Fratiglioni L. Predictors of progression from mild cognitive impairment to Alzheimer’s disease; Reply. Neurol 2008; 70:735-736.

Rosvall L, Rizzuto D, Wang HX, Winblad B, Graff C, Fratiglioni L. APOE related mortality: Effect of dementia, cardiovascular disease and gender. Neurobiol Aging 2008, Jan 29.

Simoni M, Pantoni L, Pracucci G, Palmertz B, Guo X, Gustafson D, Skoog I. Prevalence of CT-detected cerebral abnomalities in an elderly Swedish population sample. Acta Neurol Scand 2008; 118:260-267.

Brommelhoff JA, Gatz M, Johansson B, McArdle JJ, Fratiglioni L, Pedersen N. Depression as a risk factor or prodromal feature for dementia? Findings in a population-based sample of Swedish twins. Psychology & Aging 2009; 24(2):373-384.

Edin Zylberstein D, Lissner L, Björkelund C, Mehlig K, Thelle DS, Gustafson D, Östling S, Waern M, Guo X, Skoog I. Midlife Homocysteine and Late-life Dementia. A 35 year follow-up of the prospective population study of women in Gothenburg. Neurobiol Aging 2009 (in press).

Fratiglioni L, Qiu C. Prevention of common neurodegenerative disorders in the elderly. Exp Gerontol 2009; 44:46-50.

Gudmundsson P, Skoog I, Waern M, Blennow K, Zetterberg H, Rosengren L, Gustafson D. Is there a CSF biomarker profile related to depression in elderly women? Psych Res (in press).

Guo X, Pantoni L, Simoni M, Bengtsson C, Björkelund C, Lissner L, Palmertz B, Gustafson D, Skoog I. Midlife blood pressure and late-life white matter lesions: The prospective population study of women in Gothenburg, Sweden. Hypertension 2009; 54:57-62.

Gustafson D, Melchior L, Eriksson E, Sundh V, Blennow K, Skoog I. The ACE insertion deletion polymorphism relates to dementia by metabolic phenotype, APOE e4 and age of dementia onset. Neurobiol Aging (in press).

Gustafson D, Bäckman K, Waern M, Östling S, Guo X, Zandi P, Mielke M, Bengtsson C, Skoog I. Adiposity indicators and dementia over 32 years in Sweden. Neurol (in press).

Karp A, Andel R, Parker M, Wang H-X, Winblad B, Fratiglioni L. Mentally stimulating activities at work during midlife and dementia risk after age 75. A follow up study from the Kungsholmen Project. Am J Geriatr Psych 2009; 17(3):227-236.

Kivipelto M, Annerbo S, Hultdin J, Bäckman L, Viitanen M, Fratiglioni L, Lökk J. Homocysteine and holo-transcobalamin and the risk of dementia and Alzheimer’s disease: a prospective study. Eur J Neurol 2009; 16(7):808-813.

Paillard-Borg S, Wang HX, Winblad B, Fratiglioni L. Pattern of participation in leisure activities among older people in relation to their health conditions and contextual factors: A survey in a Swedish urban area. Ageing and Society 2009; 29(5):803-821.

Paillard-Borg S, Fratiglioni L, Wang HX, Winblad B, Wang HX. Leisure activities in late life in relation to dementia risk: principal component analysis. Dement Geriatr Cogn Disord 2009; 28:136-144.

Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009; 11(2):111-128.

Sacuiu S, Gustafson D, Johansson B, Thorvaldsson V, Berg S, Sjögren M, Guo X, Östling S, Skoog I. The pattern of cognitive symptoms predicts time to dementia onset. Alzh Dement 2009; 5:199-206.

Wang HX, Karp A, Herlitz A, Crowe M, Kårenholt I, Winblad B, Fratiglioni L. Personality and lifestyle in relation to dementia incidence. Neurology 2009; 72(3):253-259.

Xu L, Qiu CX, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Mid- and Late-life Diabetes in relation to the Risk of Dementia: A Population-based Twin Study. Diabetes 2009; 58: 71-77.

Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L. Uncontrolled diabetes increases risk for Alzheimer disease: a population-based cohort study. Diabetologia 2009; 52:1031-1039.

Andel R, Crowe M, Pedersen NL, Mortimer J, Crimmins E, Johansson B, Gatz M (2005):Complexity of work and risk of Alzheimer’s disease: a population-based study of Swedish twins. J Ger:  Psych. Sci, 60, P251-8.

Gatz M, Fratiglioni L, Johansson B, Berg S, Mortimer JA, Reynolds C A, Fiske A & Pedersen NL (2005): Complete ascertainment of dementia in the Swedish Twin Registry: The HARMONY study. Neurobiology of Aging. Apr;26(4):439-47

Gatz M. Fiske A, Reynolds CA, Johansson B, Fratiglioni L & Pedersen NL (2005): Performance on neurocognitive tests by co-twins to dementia cases compared to normal control twins. Journal of Ger Psychiatry and Neurology, 18, 202-207.

Heflin LA, Meyerowitz BE, Hall P, Lichtenstein P, Johansson B, Pedersen NL, & Gatz M (2005): Cancer as a risk factor for long-term cognitive deficits and dementia. Journal of the National Cancer Institute, 97, 854-856.

Lewerin C, Matousek M, Steen G, Johansson B, Steen B & Nilssson-Ehle H (2005): Significant correlations of plasma homocysteine and serum methylmalonate with movement and cognitive performance in elderly subjects but no improvement from short-term vitamin therapy: a placebo controlled randomized study. American J. Clin Nutrition, 81, 1155-1162.

Sacuiu S, Sjögren M, Johansson B, Gustafson D & Skoog I. (2005): Prodromal cognitive signs of dementia in 85-year-olds using four sources of information Neurology, 65, 1894-1900.

Wikby A, Ferguson GF, Forsey R, Thompson J, Strindhall J, Löfgren S, Nilssson B-O, Ernerudh J, Pawelec G & Johansson B. (2005): An immune risk phenotype, cognitive impairment and survival in very late life: The impact of allostatic load in Swedish Octo- and Non-genarian humans. J. Ger: Biological Sci, 60, 556-565.

Andersson C, Lindau M, Almkvist O, Engfeldt P, Johansson SE, Eriksdotter Jönhagen M. Identifying patients at high and low risk for cognitive decline using Rey Auditory Verbal Learning test among middle-aged memory clinic out-patients. Dement Cogn Disord. 21:251-259, 2006.

Gatz M, Reynolds C, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A & Pedersen NL (2006 ): The role of genes and environments for explaining Alzheimer’s disease. Arch Gen Psychiatry, 63, 168-174.

Gatz M, Mortimer J, Fratiglioni L, Johansson B, Berg S, Reynolds C & Pedersen NL (2006). Potentially modifiable risk factors for dementia in identical twins. Alzheimer’s & Dementia, 2, 110-117.

Proctor DN, Fauth EB, Hoffman L, Hofer SM, McClearn GE, Berg S & Johansson B. (2006). Longitudinal change in physical functional performance among the oldest old: insight from a study of Swedish twins. Aging Clin Exp Res., 18, 517-30.

Read S, Pedersen NL, Gatz M, Berg S, Vuoksimaa E, Malmberg B, Johansson B, & McClearn GE. (2006). Sex differences after all those years? Heritability of cognitive abilities in old age. J Gerontology: Psych Sci, 61, P137-43

Thorvaldsson V, Hofer, SM & Johansson B. (2006): Aging and late life terminal decline: A comparison of alternative modeling approaches. European Psychologist. 11, 196-203.

Thorvaldsson, V, Hofer SM, Berg S & Johansson B. (2006): Effects of repeated testing in a longitudinal age-homogenous study of cognitive aging. J.Ger: Psych Sci., 61, P348-54

Braungart Fauth E, Zarit SH, Malmberg B & Johansson B. (2007). Physical, cognitive, and psychosocial variables from the Disablement Process Model predicts patterns of independence and the transition into disability for the oldest-old. Gerontologist, 47, 613-24.

Bäckman L & Small BJ. (2007). Cognitive deficits in preclinical Alzheimer’s disease and vascular dementia: Patterns of findings from the Kungsholmen Project. Physiology & Behavior, 92, 80-86

Fischer H, Sandblom J, Nyberg L, Herlitz A & Bäckman L. (2007) Brain activation while forming memories of fearful and neutral faces in women and men. Emotion, 7, 767-773.

Gatz M, Mortimer JA, Fratiglioni L, Johansson B, Berg S, Andel R, Crowe M, Fiske A, Reynolds CA, Pedersen NL. (2007). Accounting for the relationship between low education and dementia: A twin study. Physiol Behav. 92, 232-7

Harel O, Hofer SM, Hoffman L, Pedersen NL & Johansson B. (2007). Population inference with mortality and attrition in longitudinal studies on aging: a two-stage multiple imputation method. Exp Aging Res. 33, 187-203.

Nilsson SE, Takkinen S, Berg S, Johansson B, Melander A & Lindblad U. (2007). Low systolic blood pressure is associated with impaired cognitive function in the oldest-old: longitudinal observations in a population-based sample of 80-years and older.Aging, Clin. Exp. Res.19, 1-7.

Small BJ & Bäckman L. (2007). Longitudinal trajectories of cognitive change in preclinical Alzheimer’s disease: A growth mixture modeling analysis. Cortex, 43, 826-834.

Thilers PP, MacDonald SWS & Herlitz A. (2007) Sex differences in cognition: The role of handedness. Physiology & Behavior, 92, 105-109.

Andel R, Crowe M, Pedersen N L, Fratiglioni L, Johansson B, & Gatz M. Physical exercise at midlife and risk of dementia three decades later: a population-based study of Swedish twins. Journal of Gerontology: Medical Sciences 2008; 63:62-66.

Bäckman L. Memory and cognition in preclinical dementia: What we know and what we do not know. Canadian Journal of Psychiatry 2008; 53:354-360.

Bäckman L, Lindenberger U, Li S-C & Nyberg, L. Dopamine and cognitive aging: New evidence and emerging ideas. Neuroscience and Biobehavioral Reviews. (in press).

Cervenka S, Bäckman L, Cselényi Z, Halldin C, & Farde L. Associations between dopamine D2 receptor binding and cognitive performance indicate functional compartmentalization of the human striatum. Neuroimage 2008; 40:1287-1285.

Dahlin E, Stigsdotter-Neely A, Larsson A, Bäckman L & Nyberg L. Transfer of learning after updating training mediated by the striatum. Science 2008; 320:1510-1512.

Dahlin E, Nyberg L, Bäckman L & Stigsdotter-Neely A. Plasticity of executive functioning in young and old adults: Immediate training gains, transfer, and long-term maintenance. Psychology and Aging. (in press).

Herlitz A, Thilers P & Habib R. Endogenous estrogen is not associated with cognitive performance before, during, or after menopause. Menopause, 2008; 14:425-431.

Hong MG, Reynolds C, Gatz M, Johansson B, Palmer JC, Gu HF, Blennow K, Kehoe PG, de Faire U, Pedersen NL, Prince JA. Evidence that the gene encoding insulin degrading enzyme influences human lifespan. Hum Mol Genet 2008 1;17(15):2370-2378.

Jonsson Laukka E, MacDonald S W M & Bäckman L. Terminal-decline effects for select cognitive tasks after controlling for preclinical dementia. American Journal of Geriatric Psychiatry 2008; 16:355-365.

Lindenberger U, Nagel I, Heekeren H R, Li S-C & Bäckman L. Genes, aging, and cognition. Frontiers in Neuroscience.(in press).

Lindenberger U, Nagel I E, Chicherio C, Li S-C, Heekeren H R, Bäckman L. Age-related decline in brain resources magnifies genetic effects on cognitive functioning. Frontiers in Neuroscience 2008; 2:234-244.

Livner Å, Karlsson S, Berger A-K & Bäckman L. Differential effects of depressive symptoms on prospective and retrospective memory in old age. Journal of Clinical and Experimental Neuropsychology, 2008; 30:272-279.

MacDonald S W M, Cervenka S, Nyberg L, Farde L & Bäckman L. The relationship between dopamine D2 receptor binding and within-person cognitive variability. Neuropsychologia. (in press).

MacDonald S W M, Li S-C & Bäckman L. Neural underpinnings of cognitive variability. Psychology and Aging. (in press).

MacDonald S W S, Nyberg L, Sandblom J & Bäckman L. Increased response-time variability is associated with reduced inferior parietal activation in recognition memory. Journal of Cognitive Neuroscience 2008; 20:779-786.

MacDonald S W S, Hultsch D F, Dixon R A. Predicting impending death: Inconsistency in speed is a selective and early marker. Psychol and Aging 2008; 23:595-607.

Nagel I, Chicherio C, Li S-C, von Oertzen T, Sander T, Villringer A, Heekeren H R, Bäckman L & Lindenberger U. Human aging magnifies genetic effects on executive functioning and working memory. Frontiers in Human Neuroscience 2008; 2:1-8.

Nyberg L, Dahlin E, Stigsdotter Neely A & Bäckman L. Neural correlates of variable working-memory load across adult age and skill: Dissociative patterns within the fronto-parietal network. Scandinavian Journal of Psychology. (in press).

Solomon A, Kåreholt I, Ngandu T, Wolozin B, MacDonald SWS, Winblad B, Nissinen A, Tuomilehto J, Soininen H & Kivipelto M. Cholesterol, lipid-lowering drugs, and cognitive functions: 21-year follow-up study. Neurobiology of Aging, (in press).

Spulber G, Niskanen E, MacDonald SWS, Chen K, Smilivici O, Reiman EM, Hämäläinen A, Vanninen R, Kivipelto M & Soininen H. Using whole brain atrophy rates to predict conversion from mild cognitive impairment to probable Alzheimer’s disease. Neuroimage. (in press).

Thorvaldsson V, Hofer M, Berg S, Skoog I, Sacuiu S, Johansson B. Onset of terminal decline in cognitive abilities in individuals without dementia. Neurol 2008; 71:882-887.

Wahlin Å, Fahlander K, Robins-Wahlin T-B, Bunce D & Bäckman L. Vitamin B status and cognitive performance in preclinical and clinical Alzheimer´s disease. Dementia and Geriatric Cognitive Disorders 2008; 25:23-31

Vannini P, Lehmann C, Dierks T, Viitanen M, Wahlund LO, Almkvist O. Failure to modulate neural response to increasing task demands in mild Alzheimer’s disease; an fMRI study of visuospatial processing. Neurobiol Dis 2008, May 17.

Burzynska A, Preuschhof C, Bäckman L, Nyberg L, Li S-C, Lindenberger U, Heekeren H R. Age-related differences in white-matter microstructure: Region-specific patterns of diffusivity. Neuroimage (in press)

Bäckman L. Cognitio in preclinical dementia: Current knowledge and future prospects. Acta Sinica Psychologica (in press).

Bäckman L, Lindenberger U, Li S-C, Nyberg L. Linking cognitive aging to alterations in dopaminergic neurotransmitter functioning: Recent data and future avenues. Neurosci and Biobehav Reviews (in press).

Dahlin E, Bäckman L, Stigsdotter N A, Nyberg L. Training of the executive component of working memory: Subcortical areas mediate transfer effects. Restorative Neurol and Neurosci (in press).

De Frias C, Marklund P, Eriksson E, Larson A, Öman L, Annerbrink K, Bäckman L, Nilsson L-G, Nyberg L. Influence of COMT gene polymorphism on fMRI-assessed sustained and transient activity during a working memory task. J Cogn Neurosci (in press).

Fischer H, Nyberg L, Bäckman L. Age-related differences in brain regions supporting successful encoding of emotional faces. Cortex (in press).

Karlsson S, Nyberg L, Karlsson P, Fischer H, Thilers P, macDonalt S W S, Brehmer Y, Rieckmann A, Halldin C, Farde L, Bäckman L. Modulation of striatal dopamine D1 ginding by cognitive processing. Neuroimage 2009; 48:398-204.

Kivipelto M, Annerbo S, Hultdin J, Bäckman L, Viitanen M, Fratiglioni L, Lökk J. Homocysteine and holo-transcobalamin and the risk of dementia and lzheimer’s disease: A prospective study. European J Neurol 2009; 16:808-813.

Larsson M, Farde L, Hummel T, Witt M, Erixon-Lindroth N, Bäckman L. Age-related loss of olfactory sensitivity: Association to doamine transporter binding in putamen. Neuroscience 2009; 161:422-426.

Li S-C, Chicherio C, Nyberg L, von Oertzen T, Nagel I E, Sander T, Heekeren H R, Lindenberger U, Bäckman L. Ebbinghaus revisited: Influences of the BDNF Val66Met polymorphism on backward serial recall are modulated by human aging. J Cogn Neurosci (in press).

Livner Å, Jonsson Laukka E, Karlsson S, Bäckman L. Prospective and retrospective memory in Alzheimer’s disease and vascular dementia: Similar patterns of impairment. J Neurol Sci 2009; 283:235-239.

Livner Å, Wahlin Å, Bäckman L. Thyroid-stimulating hormone and prospective memory functioning in old age. Psychoneuro-endocrinology (in press).

MacDonald S W S, Cervenka S, Nyberg L, Farde L, Bäckman L. Extrastriatal dopamine D2 receptor binding modulates intraindividual variability in episodic recognition and executive functioning. Neuropsychologia 2009; 47:2299-2304.

MacDonald S W S, Li S-C, Bäckman L. Neural underpinnings of withi-person variabitlity in cognitive functioning. Psychol and Aging (in press).

Nyberg L, Andersson M, Forsgren L, Jakobsson-Mo S, Larsson A, Marklund P, Nilsson L-G, Riklund K, Bäckman L. Striatal dopamine D2 binding is related to frontal BOLD response during updating of long-term memory representations. Neuroimage 2009; 46:1194-1199.

Nyberg L, Dahlin E, Stigsdotter N A, Bäckman L. Neural correlates of variable working-memory load across adult age and skill: Dissociative patterns within the frontoparietal network. Scand J Psychol 2009; 50:41-46.

Reynolds CA, Hong MG, Eriksson UK, Blennow K, Johansson B, Malmberg B, Berg S, Gatz M, Pedersen NL, Bennet AM, Prince JA. Sequence variation in SORL1 and dementia risk in Swedes. Neurogenetics 2009 Aug 4.

Reynolds CA, Hong MG, Eriksson UK, Blennow K, Bennet AM, Johansson B, Malmberg B, Berg S, Wiklund F, Gatz M, Pedersen NL, Prince JA. A survey of ABCA1 sequence variation confirms association with dementia. Hum Mutat 2009 Sep; 30(9):1348-1354.

Böcker och bokkapitel

Bäckman, L., & Nyberg, L. (Eds.). (in press). Memory, aging, and brain. London: Psychology Press.

Bäckman, L., & Nyberg, L. (in press). Dopamine and cognitive aging. In L. Bäckman & L. Nyberg (Eds.), Memory, aging, and brain. London: Psychology Press.

Dixon, R. A., Garrett, D. D., & Bäckman (2008). Principles of compensation in cognitive neuroscience and neurorehabilitation. In D. T. Stuss, G. Winocur, & I. H. Robertson (Eds.), Cognitive neurorehabilitation: A comprehensive approach (2nd ed., pp. 22-38). New York: Cambridge University Press.

Johansson, B. (2008). Memory and cognition in aging: Issues to consider in geropsychological assessment. In R. Woods & L. Clare (Eds.), Handbook of the clinical psychology of ageing (2nd ed.). John Wiley.

Jonsson Laukka, E., Karlsson, S., MacDonald, S. W. M., & Bäckman, L. (in press).  Cognitive functioning in vascular dementia before and after diagnosis. In L.-O. Wahlund, T. Erkinjuntti, & S. Gauthier (Eds.), Treatment of vascular dementia. New York: Cambridge University Press.

Li, S.-C., Lindenberger, U., Heekeren, H. R., Nyberg, L., & Bäckman, L. (in press). Neuromodulation and cognition across the adult life span. In W. Jagust & M. D´Esposito (Eds.), Cognitive neuroscience of aging. New York: Oxford University Press.

Nyberg, L., & Bäckman, L. (2007). Det episodiska minnet. In L. Olson (Ed.), En  bok om hjärnan (pp. 105-114). Stockholm: Karolinska Instititutet University Press.

Schäfer, S., & Bäckman, L. (2007). Normales und pathologisches kognitives Altern. In J. Brandtstädter & U Lindenberger (Eds.), Entwicklunfspsychologie der Lebensspanne: Ein Lehrbuch (pp. 245-269). Stuttgart: Kohlhammer Verlag.

Small, B. J., MacDonald, S. W. M., & Bäckman, L. (2008). Episodic memory and Alzheimer´s disease. In E. Dere, A. Easton, L. Nadel, & J Huston (Eds.), Handbook of  behavioral neuroscience: Episodic memory research (pp. 535-549). Amsterdam: Elsevier.

Thorvaldsson, V., Hofer, S. M., Hassing, L. & Johansson, B. (2007). Cognitive change as conditional of age heterogeneity in onset of mortality-related processes and repeated testing effects. In S. M. Hofer & D. F. Alwin (Eds.), Handbook of cognitive aging: Interdisciplinary perspectives. SAGE.

Immunosenescence. Landes Bioscience, Springer :USA. pp1-14 Johansson, B. (in press): Memory and cognition in aging: In B. Woods & L. Clare (eds.): Handbook of the Clinical Psychology of Ageing. Jon Wiley & Sons, Ltd., 2nd ed.

 

Omvårdnad

Bazeley M, Sousa P., Johansson S., Wijk H. (2006) The Use of National Registries Data in three European countries in order to improve patient quality International Journal of Health Care Quality Assurance; 19 (7) 551-560.

Svahn Holmén M, Robertsson B, Wijk H, Clinical usefulness of BMI, MNA-SF together with a dietary record for nurses in assessment of the nutritional status of acute geriatric patients. Nursing Older People June 2006 Volume 18 (5)31-35

Falk H. Wijk H. Natural activity – An intervention study of the interplay between cage-birds and elderly patients in a Swedish hospital setting. In press International Journal of Older people nursing 2007

Falk H. Persson L-O. Wijk H A Psychometric evaluation of a Swedish translation of Quality of Life in Late- Stage Dementia (QUALID) Scale. International Psychogeriatrics (2007) 19:6, 1040-1050

Larsson A.,Wijk H. Patient experiences of pain and pain management at the end of life: a pilot study. Pain Management Nursing, 2007, 8 (1), 12-16

Robertsson B., Nordström M., Wijk H. Investigating Poor Insight in Alzheimer´s Disease. A survey of research approaches.  Dementia: The international journal of social research and practice Volume 6(1) 45-61 2007

Stenwall E, Sandberg J, Eriksdotter Jönhagen M, Fagerberg I. Encountering the older confused patient: professional carers experiences. Scand J Caring Sciences, 21:515-522, 2007.

Wijk, H. Grimby A. A pilot-study of needs in palliative care. American journal of hospice and palliative medicine American Journal of Hospice and Palliative Medicine, 9 2007.

Benkel I, Wijk H, Molander U. Family and friends provide most social support for the bereaved. Palliative Medicine, in press 2008.

Edberg, A-K, Bird, M, Richards, D. & Woods, B, Keeley, P. & Davis-Quarrell, V. (2008) Strain in nursing care of people with dementia: nurses’ experience in Australia, Sweden and United Kingdom. Aging and Mental Health, 2008;12:236-243.

Edvardsson D. Therapeutic environments for older people, a descriptive and interpretative study. J Gerontol Nursing 2008:34:32-40.

Edvardsson D, Sandman PO, Nay R, Karlsson S. Associations between the working characteristics of nursing staff and the prevalence of behavioral symptoms in people with dementia in residential care. Int Psychoger 2008:20;764-776.

Edvardsson D, Sandman PO, Rasmussen B. Construction and psychometric evaluation of the Swedish language Person-Centred Climate Questionnaire – Patient version. J Advanced Nursing 2008:63;302-309.

Edvardsson D, Katz B, Nay R. The Aged Care Pain Chart – an innovative approach to assessing, monitoring  and documenting pain in older people. Australian J Ageing 2008:27;93-96.

Edvardsson D, Winblad B, Sandman PO. Person-centered care of people with severe Alzheimer’s disease: A current status and ways forward. Lancet Neurology 2008:7;362-367.

Edvardsson D, Sandman PO, Nay R, Karlsson S. Predictors of job strain in nursing staff working with people with dementia. J Nursing Management, (in press).

Edvardsson D. Balancing between being a person and being a patient – a qualitative study of patient specific hospital clothing. Int J Nursing Studies, (in press).

Isaksson U, Åström S, Sandman PO, Karlsson S. Prevalence of violence among residents living in nursing homes. Environmental, organizational, caregivers’ and residents’ characteristics explaining the variance. J Clin Nursing, (in press).

Jönsson P. Wijk H. Danielson E. Persons living with bipolar disorder – their view of the illness and the future, (in press).

Modh-Hinnersson K, Wijk H. The effect of a 1-year trainee program for the development of practical skills for newly graduated nurses in pediatric care, in relation to Benners nursing domains. (In Swedish: Betydelsen av ett 1-årigt traineeprogram för praktisk färdighetsutveckling av nyutexaminerade sjuksköterskor inom barn- och ungdomssjukvård i relation till Benners omvårdnadsdomäner, (in press).

Nay R, Bird M, Edvardsson D, Flemming R, Hill K. Person centred care. Nursing Older People, (in press).

Stenwall E, Sandberg J, Eriksdotter Jönhagen M, Fagerberg I. Relatives lived experience of encountering the older person with confusion: Experiencing unfamiliarity in a familiar person. Int J Older people Nursing, in press 2008.

Stenwall E, Eriksdotter Jönhagen M, Sandberg J, Fagerberg I: The older patient´s experience of encountering professional carers and close relatives during a confusional state: an interview study. Int J Nursing studies, in press 2008

Wijk H. Putting evidence into practice. A model supporting the health care sector with evidence-based knowledge by integrating methods for research and profound knowledge of improvement in the curriculum of health care educations on advanced level. Quality and Safety in Health Care, 2008, volume 17, issue 4.

Wångblad C, Wijk H, Dahlin Ivanoff S. Experiences of physical strain during person transfer situations in dementia care. Scandinavian Journal of Caring Sciences, in press 2008.

Edvardsson D, Sandman PO, Rasmussen B. Development and psychometric properties of the Swedish Person-Centred climate questionnaire, staff version. J Nursing Management (accepted for publication)

Edvardsson D, Koch S, Nay R. Psychometric evaluation of the English version Person-Centred climate questionnair, patient version. western J Nursing Res 2009; 31:235-244.

Edvardsson D, Koch S, Nay R. Psychometric evaluation of the English version Person-Centred climate questionnaire, staff version. J Nursing Management (accepted for publication).

Edvardsson D, Fetherstonhaugh D, Gibson S, Nay R. Development and initial testing of the Person-Centred care assessment tool (P-CAT). Int Psychoger (accepted for publication).

Edvardsson D, Fetherstonhaugh D, Nay R. Promoting a continuation of self and normality: person-centred care as described by people with dementia, family members and aged care staff. J Clin Nursing (accepted for publication).

Edvardsson D. Personcentrerad omvårdnad: En introduktion (Red). Lund: Studentlitteratur (in press).

Edvardsson D, Wijk H. Omgivningens betydelse för hälsa och vård. Omvårdnadens grunder, Lund: Studentlitteratur 2009.

Falk H, Wijk H, Persson LO. The effects of refurbishment on resident’s quality of life and wellbeing in two Swedish residential care facilities. Health & Place  2009; 15: 717-724.

Wijk H. (2001) Färguppfattning vid hög ålder. Nordisk Geriatrik No 4 5-9

Wijk H. (2004) Goda vårdmiljöer för äldre – en del av behandlingen. Nordisk Geriatrik No 2  58-63

Antonsson S, Robertsson B, Wijk H  (2005) Kan personer med demens öka i vikt med hjälp av majsersättning? Nordisk Geriatrik No 4

Falk H, Wijk H. (2005) Kan djur i vården lindra mental trötthet hos äldre? Nordisk Geriatri No 6

Benkel I., Wijk H. (2006) ”Bara att det finns någon där”. Socialt stöd till närstående efter dödsfall på en palliativ enhet. Nordisk Geriatrik No 1. 4-6.

Winter M, Wijk H (2006) Äldre och bilkörning Nordisk Geriatrik No 4

Robertsson B., Nordström M., Wijk H. (2006) Olika perspektiv på sjukdomsinsikt vid Alzheimers sjukdom. Nordisk geriatrik (5) 30-33

Wijk H, Särnwald K. (2006) Smärtbehandling och äldre. Nordisk geriatrik (6) 28-30

Brask A-K. Wijk H. Snabb och säker bedömning av nutritionsstatus hos patienter med Hjärtsvikt/KOL. (2007)  Nordisk geriatrik (4)

Falk H. Persson L-O., Wijk H (2007) Utvärdering av en svensk version av QUALID-skalan Nordisk Geriatrik nr 5 38-39

Wijk H: Färg i vårdmiljön. I Färg och ljus. Red: Karin Fridell Anter. Kungliga Tekniska högskolan, Stockholm

Evaluating Dementia Care. Ed. Anthea Innes & Louise McCabe Department of Applied Social Science, University of Sterling. Wijk H. Evaluating long stay Care setting: the environment. 2006

Kvalitetsutveckling inom hälso- och sjukvård, Göransson C, Skärsäter I, Wijk H. I Omvårdnad Liber 2006

 

Rehabilitering

Gunnarsson N, Marklund B, Ahlstedt S, Borell L, Nordström G. Allergy-like conditions and health care outcomes  among children with exclusion diets at schools. Scan J Caring Sci. 2005;19:46-52.

Öhman, A. & Nygård, L. (2005). Meanings and motives for engagement in daily occupations among individuals with Alzheimer’s disease. Occupational Therapy Journal of Research, 25, 89-97.

Borell L.  Asaba E.  Rosenberg L.  Schult M.  Townsend E. Exploring experiences of ”participation” among individuals living with chronic pain.  Scand J of Occpl Ther. (2006) 13(2): 76-85.

Nygård, L. & Winblad, B. (2006). Measuring long term effects and changes in the daily activities of people with dementia. Journal of Nutrition, Health and Aging, 10 (2):137-138.

Nygård, L. (2006). How can we get access to the experiences of people with dementia? Suggestions and reflections. Scandinavian Journal of Occupational Therapy, 13, 101-112.

Margot, I. & Nygård, L. (2006). Access technology and dementia care: Influences in a secured unit. Scandinavian Journal of Occupational Therapy, 13, 113-124.

Nygård L, Starkhammar S. (2007). The use of everyday technology by people with dementia living alone. Aging and Mental Health, 11(2), 144-155.

Andersson Svidén, G., Tham, K., & Borell, L. Involvement in everyday life for people with a life threatening illness. Palliative & Supportive Care, (in press).

Borell L. Occupational therapy for older adults: Investments for progress. British J Occup Ther 2008; 71(11): 482-286.

Erikson, A, Karlsson, G., Borell, L. & Tham, K. The lived experience of memory impairment in daily occupation after acquired brain injury – One year of rehabilitation. OTJR: Occupation, Participation and Health, (in press).

Johansson, K. Lilja, M,. Petersson I, & Borell L. Performance of activities of daily living in a sample of applicants for home modification services. Scan J Occ Ther, (in press).

Nygård L, Starkhammar S, Lilja M. The provision of stove timers to individuals with cognitive impairment. Scandinavian Journal of Occupational Therapy, in press (available online).

Nygård L. The meaning of everyday technology as experienced by people with dementia who live alone. Dementia 2008; 7(4): 481-502.

Starkhammar S, Nygård L. Using a timer device for the stove: Experiences of older adults with memory impairment or dementia and their families. Technology and Disability 2008; 20:189-191.

Vikström S, Josephsson S & Nygård L. Engagement in occupations: experiences of persons with dementia and their caregiving spouses. Dementia, (in press).

Öhman A, Josephsson S & Nygård L. Awareness through interaction in everyday occupations: Experiences of people with Alzheimer’s disease. Scandinavian Journal of Occupational Therapy 2008; 15:43-51.

Boman I-L, Borell L, Tham K, Bartfai A, Hemmingsson H. Support in everyday activities with a home-based electronic memory aid for persons with memory impairments. Disability and Rehab: Assistive Technology (in press).

Malinowsky C, Nygård L, Kottorp A. Psychometric evaluation of a new assessment of the ability to manage technology in everyday life for persons with mild Alzheimer’s disease, mild cognitive impairment or older adults without cognitive impairment. Scand J Occup Ther (accepted for publication).

Rosenberg L, Kottorp A, Winblad B, Nygård L. Perceived difficulty in everyday technology use among older adults with or without cognitive deficits. Scand J Occup Ther 2009 EPUB ahead of print.

Rosenberg L, Nygård L, Kottorp A. Everyday Technology Usage (ETUQ) – psychometric evaluation of a new assessment of competence in technology use. Occup Ther J Res, EPUB ahead of print.

 

Hälsoekonomi och primärvård

Nordberg G, von Strauss E, Kåreholt I, Johansson L, Wimo A. The amount of informal and formal care among non-demented and demented elderly persons – results from a Swedish population based study. Int J Geriatr Psychiatry 2005;20:862-71.

Wimo A, Viitanen M, Sonde L, Johansson K, Winblad B. Färdtjänst I Nordanstig och på Kungsholmen, Stockholm. Slutrapport till projektet Samhällsekonomiska och individuella konsekvenser av inskränkt mobilitet – behovet av färdtjänst. SNAC rapport nr 9, Stiftelsen Äldrecentrum, Stockholm, 2005.

Ekman M, Berg J, Wimo A, Jönsson L,  McBurney C. Health utilities in mild cognitive impairment and dementia: A population study in Sweden. Int J Geriatr Psychiatry 2006 Nov 29.

Linus Jönsson, Maria Eriksdotter Jönhagen, Lena Kilander, Hilkka Soininen, Merja Hallikainen, Gunhild Waldemar, Harald Nygaard, Niels Andreasen, Bengt Winblad, Anders Wimo. Determinants of costs of care for patients with Alzheimer’s disease.  Int J Geriatr Psychiatry 2006;21:449-59.

Linus Jönsson, Niels Andreasen, Lena Kilander, Hilkka Soininen, Gunhild Waldemar, Harald Nygaard, Bengt Winblad, Maria Jönhagen, Merja Hallikainen , Anders Wimo. Patient- and proxy-reported utility in Alzheimer’s disease using the EuroQoL.  Alzheimer Dis Assoc Disord  2006 January/March;20(1):49-55.

Wimo A, Jonsson L, Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 2006;21:175-181.

Boström F, Jönsson L, Minthon L, Londos EC. Patients with Lewy Body Dementia use more resources than those with Alzheimer’s disease. Int J Geriatr Psychiatry 2007 Aug;22(8):713-9.

Nordberg G, Wimo A, Jönsson L, Sjölund B-M, Lagergren M, von Strauss E. Time use and costs of institutionalised elderly persons with or without dementia: results from the Nordanstig cohort in the Kungsholmen Project-a population based study in Sweden. Int J Geriatr Psychiatry. 2007 Jul;22(7):639-48.

Nordberg G, Wimo A, Jönsson L, Sjölund BM, Lagergren M, von Strauss E. Time use and costs of institutionalised elderly persons with or without dementia: results from the Nordanstig cohort in the Kungsholmen Project – a population based study in Sweden. Int J Geriatr Psychiatry 2007 Jul;22(7):639-48.

Wimo A, Nordberg G. Validity and reliability of assessments of time. Comparisons of direct observations and estimates of time by the use of the RUD (Resource Utilization in Dementia)-instrument. Arch Gerontol Geriatr 2007;44(1):71-81.

Wimo A, Norlund A. Cost–effectiveness of treatments for Alzheimer’s dementia. Expert Review of Pharmacoeconomics & Outcomes Research, February 2007;7(1):83-90.

Wimo A. Clinical and economic outcomes – friend or foe? Int Psychogeriatr. 2007 Jun;19(3):497-507.

Wimo A, Norlund A. Commentary on ”Health economics and the value of therapy in Alzheimer´s disease. ”Cost-effectiveness-studies. Alzheimer´s and Dementia, 2007;3: 157-161

Wimo A, Jönsson L. Winblad  B. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimer´s and Dementia, 2007;3:81-91.

Wimo A, Johansson L, Jönsson L. Demenssjukdomarnas samhällskostnader och antalet dementa i Sverige 2005. Socialstyrelsen (underlag från experter), Stockholm, 2007 (artikel nr 2007-123-32).

Wimo A, Jönsson L, Winblad B. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimer’s and Dementia 2007;3:81-91.

Wimo A, Johansson L, Jönsson L. Demenssjukdomarnas samhällskostnader och antalet dementa i Sverige 2005. Socialstyrelsen (underlag från experter), Stockholm 2007 (artikel nr 2007-123-32). Sep 2007.

Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K. Luchsinger JA, Ogunniyi A, Perry E K, Potocnik F, Prince M, Stewart R, Wimo A, Zhang ZX, Antuono P; for the World Federation of Neurology Dementia Research Group. Alzheimer’s disease and vascular dementia in developing countries: prevalence, management and risk factors. Lancet Neurol 2008 Sep; 7(9):812-826.

Wimo A. Regional patterns. Northern Europe: The societal costs of dementia in Sweden. In: Alzheimer Europe. Dementia in Europe. Yearbook 2008; 71. Alzheimer Europe, Luxembourg.

Wimo A, Jönsson L, Gustavsson A. The cost of illness and burden of dementia in Europe. In: Alzheimer Europe. Dementia in Europe. Yearbook 2008; 67-70. Alzheimer Europe, Luxembourg.

Gustavsson A et al. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer’s disease and dementia with Lewy bodies. Int J Geriatr Psyshiatry. EPUB ahead of print.

Gustavsson A et al. Willingness-to-pay for reductions in care need: estimating the value of informal care in Alzheimer’s disease. Int J Geriatr Psychiatry (in press).

Jönsson L, Wimo A. The cost of dementia in Europe: a review of the evidence, and methodological considerations. Pharmacoeconomics 2009; 27(5): 391-403.

Wimo A, Johansson L, Jönsson L. Har demenssjukdomarnas samhällskostnader förändrats mellan 2000 och 2005? Läkartidningen 2009, Apr  28-May 12; 106 (18-19):1277-1282.

 

Informationsteknologi  (e-hälsa)

Lindgren H, Eriksson S. Managing Knowledge for Decision Support in the Investigation of Cognitive Disorders. In: Proc. of MIE 2005, CD-version.

Lindgren H, Eriksson S, Eklund P. Decision-Support System for the Investigation of Dementia. International Psychogeriatrics 2005;17(2):277.

Lindgren H. Managing Knowledge in the Development of a Decision-Support System for the Investigation of Dementia. Licentiate thesis. UMINF 01/05. Umeå University, 2005.

Lindgren H, Eklund P. (Logic of Dementia Guidelines in a Probabilistic Argumentation Framework. In L. Godo (Ed) ECSQARU 2005, LNAI 3571, pp. 341-352, Springer-Verlag Berlin Heidelberg, 2005.

Lindgren H, Eklund P. Differential diagnosis of dementia in an argumentation framework. Journal of Intelligent & Fuzzy Systems 2005;16:1-8.

Eklund P, Lindgren H. (2006) Towards Dementia Diagnosis Logic. In: Proc. of IPMU’06.

Lindgren H. Decision Support in Dementia Care: Developing Systems for Interactive Reasoning. PhD Thesis, UMINF 07.02. Department of Computing Science, Umeå University, 2007.

Lindgren H. DMSS – Dementia management and support system for interactive reasoning and decision-making. Int Psychoger 2007;19(1):281-282

Eklund P, Helgesson R, Lindgren H. Towards refinement of clinical evidence using general logics. In: Rutkowski L, Tadeusiewicz R, Zadeh LA, Zurada JM (Eds). Artificial Intelligence and Soft Computing – ICAISC 2008, LNCS 5097, pp 1029-1040, Springer Berlin/Heidelberg.

Lindgren H. (2008) Collaborative knowledge building for Decision-Support system development. In: Forbig P, Paternó F, Pejtersen MA. (Eds) Human-Computer Interaction Symposium (HCIS2008). IFIP 272, pp 201-206, Springer Boston.

Lindgren H. (2008) Conceptual model of activity as tool for developing a dementia care support system. In: Ackerman M, Dieng-Kuntz R, Simone C, Wulf V (Eds). Knowledge Management in Action. IFIP 270, pp 97-109, Springer Boston.

Lindgren H. Decision system supporting clinical reasoning process – an evaluation study in dementia care. Studies in Health Technology and Invormatics 2008; 136:315-320, IOS Press

© 2010 Swedish Brain Power